

1 **TITLE**

2 Systems immunology reveals the molecular mechanisms of heterogeneous influenza
3 vaccine response in the elderly

4

5 **AUTHORS**

6 Saumya Kumar^{1,2#}, Martijn Zoodma^{1,2#}, Nhan Nguyen^{1,2}, Rodrigo Pedroso³, Stephanie
7 Trittel⁴, Peggy Riese⁴, Javier Botey-Bataller^{1,2,5}, Liang Zhou^{1,2}, Ahmed Alaswad^{1,2}, Haroon
8 Arshad^{2,9}, Mihai G. Netea^{5,6}, Cheng-Jian Xu^{1,2,5}, Frank Pessler^{1,7}, Carlos A. Guzmán^{1,4}, Luis
9 Graca³, Yang Li^{1,2,5,8,10,*}

10

11 **AFFILIATIONS**

- 12 1. Centre for Individualised Infection Medicine (CiiM), a joint venture between the
13 Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH),
14 Feodor-Lynen-Straße 7, 30625 Hannover, Germany.
- 15 2. TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research
16 (HZI) and the Hannover Medical School (MHH), Feodor-Lynen-Straße 7, 30625
17 Hannover, Germany.
- 18 3. Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina,
19 Universidade de Lisboa, Lisboa, Portugal.
- 20 4. Department Vaccinology and Applied Microbiology, HZI, Inhoffenstraße 7, 38124
21 Braunschweig, Germany
- 22 5. Department of Internal Medicine and Radboud Center for Infectious Diseases,
23 Radboud University Medical Center, Geert Grooteplein Zuid 8, 6525 GA Nijmegen,
24 the Netherlands.
- 25 6. Department of Immunology and Metabolism, Life and Medical Sciences Institute
26 (LIMES), University of Bonn, Bonn, Germany.
- 27 7. Research Group Biomarkers for Infectious Diseases, TWINCORE, Feodor-Lynen-
28 Straße 7, 30625 Hannover, Germany.
- 29 8. Cluster of Excellence Resolving Infection Susceptibility (RESIST; EXC 2155),
30 Hannover Medical School, Hannover, Germany.
- 31 9. Present address: Department of Pharmaceutical Sciences, University of Faisalabad,
32 Faisalabad 38000, Pakistan.

33

34 **AUTHOR LIST FOOTNOTES**

35 # These authors contributed equally

36 ¹⁰ Lead contact

37 * Correspondence: yang.li@helmholtz-hzi.de (Y.L.)

38

39 **HIGHLIGHTS**

- 40 1. Pre-vaccination pro-inflammatory status impedes vaccine responsiveness in the
41 elderly.
- 42 2. Multi-omics integration reveals key molecules involved in vaccine response.
- 43 3. High pre-vaccination concentrations of IL-15 suppresses vaccine response through
44 NK cell activation.
- 45 4. Certain long-chain fatty acids may act as modulators against chronic inflammation
46 and are potential targets to improve vaccine response.

47

48

49 **SUMMARY**

50

51 Vaccination-induced protection against influenza is greatly diminished and increasingly
52 heterogeneous with age. We investigated longitudinally (up to five timepoints) a cohort of
53 234 elderly influenza vaccinees across two independent seasons including up to six
54 modalities (multi-omics and immunological parameters). System-level analyses revealed
55 responders exhibited time-dependent changes attributed to a productive vaccine response
56 across all omics layers whereas non-responders did not follow such dynamics, suggestive of
57 systemic dysregulation. Through multi-omics integration, we identified key metabolites and
58 proteins and their likely role in immune response to vaccination. High pre-vaccination IL-15
59 concentrations negatively associated with antibody production, further supported by
60 experimental validation in mice revealing an IL-15-driven NK-cell axis with a suppressing
61 role on antibody production. Finally, we propose certain long-chain fatty acids as modulators
62 of persistent inflammation in non-responders. Our findings highlight the potential for
63 stratification of vaccinees and open avenues for possible pharmacological interventions to
64 enhance vaccine responses.

65

66 **Key words:** Systems immunology, influenza vaccination, elderly, IL-15, NK cells, long-chain
67 fatty acids, multi-omics integration

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98 INTRODUCTION

99

100 Influenza epidemics are major public health threats, with more than 400,000 fatalities
101 estimated worldwide per year, mostly among the elderly¹. Inactivated subunit influenza
102 vaccination has proven to be the best preventive and cost-effective approach for inducing
103 protective immune memory^{2,3}. However, many factors, particularly old age, have been
104 strongly associated with a reduced protection despite vaccination^{4,5}. Consequently, the
105 elderly population is more vulnerable to influenza infection and influenza-associated
106 mortality¹.

107

108 The inefficiency in generating protective immunity in the elderly has been attributed to the
109 ageing of the immune system, which is often characterised by lingering low-grade
110 inflammation and immunosenescence⁶. Our recent studies also showed that non-responders
111 are specifically characterized by multiple suppressive immune mechanisms affecting
112 regulatory T and B cells⁷. Earlier studies have also shown higher proportions of inflammatory
113 monocytes and cytotoxic NK cells in the elderly compared to the younger population, along
114 with lower B cell responses⁸ that were attributed to intrinsic defects in T and B cells.
115 Additionally, the elderly accumulate pro-inflammatory B cells that are unable to respond to
116 influenza vaccination^{9,10}. At the molecular level, lower AP-1 activity along with enhanced
117 antiviral and interferon signalling in myeloid cells has been associated with a productive
118 vaccination response¹¹. Higher AP-1 activity induces activation of pro-inflammatory
119 cytokines, which may contribute towards a higher inflammatory status^{11,12}. However, in the
120 younger population (< 50 years), pre-vaccination pro-inflammatory status driven through NF-
121 kB signalling has been associated with high antibody response¹³. In addition to cytokines,
122 metabolites may also serve as important regulators of immune responses^{14,15}. Differences in
123 metabolite profiles between young and elderly individuals have been reported, along with
124 differential metabolic regulation of the immune response to vaccination¹⁶. Post-vaccination,
125 young high responders showed reduced concentrations of polyunsaturated fatty acids
126 (PUFAs), whereas cholesteryl esters accumulated more in elderly high responders¹⁶. Purine
127 metabolism and glycine, serine and threonine metabolism have also been associated with
128 the vaccine response¹⁶. Together, these studies have indicated complex and age-dependent
129 metabolic regulation of the antibody response to vaccination.

130

131 Here, we used a systems immunology approach to examine the differential responsiveness
132 to influenza vaccination within a previously well-established elderly cohort spanning two
133 independent influenza seasons^{7,17-19}. The transcriptional signatures of the highest and
134 lowest responders allowed us to identify a chronic inflammatory signature that is distinct from
135 the inflammatory signature supporting the vaccine response. We also show distinct changes
136 in the plasma proteome and metabolome abundance upon vaccination in high and low
137 responders. Furthermore, we identified pre-vaccination protein biomarkers associated with
138 poor vaccine response. Additionally, we identified pre-vaccination metabolites associated
139 with vaccine response, which may serve as potential modulators of the chronic inflammation
140 in the elderly. Taken together, these findings illustrate that an increased pro-inflammatory
141 profile is detrimental to influenza vaccine response in the elderly population. Results from
142 this study provide insight into the immunological processes driving differential
143 responsiveness to vaccination, and will open novel opportunities for improved vaccine

144 design as well as modulation of the immune system to enhance the vaccine response in the
145 elderly.

146

147

148 **RESULTS**

149

150 ***Demographic characteristics and their association to vaccine response in the elderly***

151

152 We collected whole blood and plasma samples from 234 trivalent inactivated influenza
153 vaccine (TIV)-vaccinees aged 65 and above in Hannover, Germany across two influenza
154 seasons and generated a multimodal dataset covering whole blood transcriptome, plasma
155 proteome, plasma/serum metabolome, and serology from up to five time points (pre-
156 vaccination, days one-three, six-seven, 21-35 and 60-70 post-vaccination). By doing this,
157 different stages of the vaccination response were covered (Figure 1A). Examining the
158 serological data, we observe heterogeneity across the elderly donors, with the majority of
159 donors showing sufficient antibody responses expected to confer protection. Donors were
160 evaluated based on their antibody fold change (day 35 vs pre-vaccination) against the three
161 strains included in the TIV vaccine⁷, and categorised as Triple Responders (TR, >4-fold rise
162 in antibody titres against all three strains), Non Responders (NR, <4-fold rise in titres against
163 all three strains), or Other (>4-fold rise in titres against one or two of the vaccine strains;
164 Figure 1B). As we have access to data from two independent seasons, we used the larger
165 cohort (season 2015/2016, n=200) as a discovery cohort, and the smaller cohort to replicate
166 our findings (season 2014/2015, n=34).

167

168 We observed another layer of heterogeneity among donors based on pre-vaccination
169 antibody titres. Previous studies have discussed the impact of high pre-vaccination
170 hemagglutination inhibition (HAI) titres that lead to reduced antibody fold change upon
171 vaccination^{8,20-22}. Within our cohort, approximately one-third of the donors (H1N1:36%,
172 B:34%, H3N2:33%) followed this pattern. Nevertheless, the majority of responders in this
173 cohort (TRs and Others) still showed a high antibody response to vaccination that was
174 independent of pre-vaccination titres, suggesting that pre-vaccination titres are not the only
175 variable defining the vaccine response (Figure 1B). Consistent positive correlations among
176 antibody titres against the three influenza strains and positive correlations between HAI titres
177 and microneutralization (MN) titres per strain were observed (Supplementary Figure 1A-1B).
178 We did not observe statistically significant differences in serological responses between
179 elderly males and females (Supplemental Figure 1C). Across two seasons, we observed a
180 significant negative correlation of antibody titres with age for the H1N1 strain, but not for the
181 H3N2 and B strains (Supplementary Figure 1D). These observed patterns were replicated in
182 the smaller cohort.

183

184

185 ***Distinct transcriptional signatures between elderly triple and non-responders***

186

187 We first evaluated transcriptome data generated from the 10 highest (TRs) and 10 lowest
188 (NRs) responders to identify transcriptional differences between the groups and the
189 transcriptomic dynamics of vaccine response resulting in 1466 significantly differentially
190 expressed genes (DEGs) (adj. p-value < 0.01, Figure 1C). Functional significance of the
191 differential transcriptome profiles between TRs and NRs (independent of time) was identified

192 using gene set enrichment analysis (GSEA) with blood transcriptome modules (BTMs)²³ as
193 background (Supplementary Data 1). We found that the top 40 most significantly enriched
194 modules showed a consistent upregulation of T and B cell related, and T cell activation
195 modules in TRs, whereas NRs showed upregulation of inflammatory and inflammatory
196 signalling modules (Figure 1D). These pathways were consistently upregulated in TRs and
197 NRs at all time points, including pre-vaccination. These differences were also reflected by
198 different proportions of immune cell populations in these donors using transcriptome
199 deconvolution (CIBERSORT²⁴, Figure 1E and Supplementary Figure 2A). In line with our
200 enrichment results, we found that TRs had higher proportions of T and B cells, whereas NRs
201 showed elevated proportions of neutrophils. These results agree with reported flow
202 cytometry results⁷ and with the observed trend of higher neutrophils in NRs at the pre-
203 vaccination time point (Supplementary Figure 2B). Despite enrichment of monocyte-related
204 BTMs in NRs, we did not observe differences in monocyte proportions between TRs and
205 NRs in deconvolution or cell blood counts. This suggests higher activity of monocytes in NRs
206 irrespective of cell proportions (Figure 1E and Supplementary Figure 2B).

207
208 We next evaluated the pre-vaccination BTMs alone that separate TRs from NRs. We found
209 TRs showed enrichment for T cell activation and signalling, Th2 differentiation and plasma/B
210 cell modules (Figure 2A, Supplementary Data 2). A recent study described a high
211 inflammatory pre-vaccination endotype that is predictive of high vaccine responders in
212 adults, but not in the elderly¹³. In line with these results, we did not observe enrichment of
213 inflammatory BTMs at the pre-vaccination time point in TRs. Instead, we observed an
214 opposite pattern, in which TRs had lower enrichment of inflammatory modules compared to
215 NRs (Supplementary Figure 3A). When we evaluated the expression patterns of the genes
216 enriched in these pathways, we found only CD83 and IL23A to be significantly upregulated
217 in TRs at all time points, suggesting that only select genes are important in elderly TRs and
218 support the immune response (Supplementary Figure 3B). While we observed a gene
219 expression pattern associated with cells engaged in humoral responses in TRs (which is in
220 line with their high responsiveness to vaccination), the NRs presented a consistently
221 upregulated inflammatory signature.

222

223

224 ***Major differences in post-vaccine transcriptional dynamics between elderly triple and*** 225 ***non-responders***

226

227 We then assessed transcriptional changes resulting from vaccination over time, in each
228 group separately. Based on significant DEGs at each time point compared to pre-
229 vaccination, we observed distinct post-vaccination dynamics between TRs and NRs. TRs
230 showed an early response at three days post-vaccination, evident from a small proportion of
231 DEGs, followed by the highest change in gene expression at day seven before going back to
232 pre-vaccination gene expression levels. However, NRs did not show significant DEGs at any
233 time point post-vaccination compared to pre-vaccination (Figure 2B and Supplementary
234 Figure 3C). Interestingly, ~18% of genes significantly upregulated at day three in TRs were
235 also significantly upregulated in NRs at all time points (Figure 1C and 2C). Functionally, the
236 day three transcriptomic profile was enriched in innate immune modules related to antiviral,
237 interferon and complement activation (Supplementary Figure 3D, Supplementary Data 3).
238 Consequently, the upregulated inflammatory genes in NRs were categorised in two clusters
239 depending on their expression patterns: "Transiently up day 3 TRs" or "Consistently up NRs"

240 (Figure 1C and 2C). While “Transiently up day 3 TRs” genes were involved in antiviral
241 response, the “Consistently up NRs” genes were enriched for modules related to AP-1
242 transcriptional network, neutrophils and other inflammatory signalling modules, which may
243 suggest a chronic inflammatory status in NRs (Figure 1C, 2D). These results highlight that
244 TRs mounted an immune response evident from transcriptional changes at different time
245 points (percentage of DEGs at day three and day seven) post-vaccination. However, NRs
246 maintained an inflammatory profile at all time points, which in turn may impede mounting the
247 vaccine response.

248

249

250 ***Elderly non-responders show higher activation of NK cells seven days post***
251 ***vaccination.***

252

253 We next examined day seven transcriptional changes in TRs and NRs separately in greater
254 detail, as day seven showed the highest change in gene expression in TRs compared to pre-
255 vaccination (Figure 2B). GSEA results in TRs showed strong positive enrichment of multiple
256 modules particularly related to cell cycle, plasma cells, immunoglobulins and T cell
257 activation, among others. Even though NRs did not show statistically significant DEGs seven
258 days post vaccination compared to pre-vaccination, GSEA at this time point showed very
259 few enrichments related to cell cycle, T cell activation and plasma cells. However, the
260 inflammatory modules were downregulated in both groups compared to pre-vaccination
261 (Supplementary Figure 3E, Supplementary Data 3).

262

263 We associated the enriched modules with cell proportions identified through transcriptome
264 deconvolution. Cell cycle modules were strongly associated with plasma cells in TRs (FDR <
265 0.05) suggesting clonal expansion of plasma cells, whereas cell cycle modules in NRs did
266 not show significant associations with any cell subsets (Figure 2E, left). Transcriptional
267 changes, particularly in plasma cells and B cells seven days post vaccination have also been
268 shown through single-cell studies²⁵. Plasma cell proportions transiently increased at this time
269 point for TRs, whereas this was not seen in NRs (Figure 1E). This observation is supported
270 by previous studies which showed that an increase in antibody secreting cells at day seven
271 correlates positively with high antibody fold change²⁶. Instead, activation modules were
272 strongly positively associated with NK and CD8 T cells in NRs. We also observed similar
273 associations in TRs, but they were weaker than in NRs (Figure 2E). The deconvolution
274 results also show higher proportions of activated NK cells in NRs (Figure 1E). Flow
275 cytometry on donors from the replication cohort also confirmed these findings
276 (Supplementary Figure 4). A higher proportion of NK cells in NRs compared to TRs has also
277 been reported in the single-cell dataset⁷. Increased NK cell proportions and activity in the
278 elderly compared to younger adults has been previously reported⁸. In addition, a significant
279 negative association of neutrophils with T cell activation BTMs in NRs suggests modulation
280 of T cell activation by neutrophils. Finally, in NRs, Tregs were negatively associated with
281 immune activation BTM, which may suggest attempts at suppression of inflammation in
282 response to vaccination. Altogether, the observed associations link cell subsets to the
283 functional changes characterised through BTMs and highlight multiple differences in TRs
284 and NRs post-vaccination. Particularly, we observe higher NK cell proportions and higher
285 activation of NK cells as a characteristic of the elderly NRs.

286

287

288 ***Post-vaccination plasma proteome and metabolome differences between triple and***
289 ***non-responders highlight key molecules involved in vaccination response***

290

291 We next evaluated the proteome (Olink-Explore 384 panel) profile between all TRs (n=71)
292 and NRs (n=10) in our cohort, measuring up to 311 proteins. Differential abundance testing
293 between TRs and NRs irrespective of time showed higher CLEC7A in TRs in the discovery
294 cohort (adj. p = 0.03, moderated t-test,), but not in the replication cohort possibly because of
295 the small effect size (Supplementary Figure 5A, 5B). We next examined protein dynamics
296 induced by vaccination separately in TRs and NRs by comparing each time point to pre-
297 vaccination. Unlike the distinct dynamics observed at the transcriptome level in TRs and
298 NRs, changes in protein abundance in both TRs and NRs seven days post-vaccination were
299 observed (Figure 3A, Supplementary Data 4). In TRs, 14 proteins were upregulated at seven
300 days post-vaccination (Figure 3B), among which TNFRSF13B (also known as TAC1) has
301 been widely described for its role in B cell proliferation and plasma cell differentiation^{20,27,28}.
302 Other proteins upregulated in TRs include IFNLR1^{29,30}, a receptor for type three interferons;
303 CCL3³¹ or MIP1a, CD48 and SLAMF7. TNFRSF13B, IFNLR1 and CCL3 also showed a
304 trend of increased abundance in the replication cohort at day seven post-vaccination
305 (Supplementary Figure 5B). On the other hand, five distinct proteins were upregulated in
306 NRs at day seven post-vaccination, including PARP1, EGLN1 and SERPINB8. PARP1 plays
307 a role in oxidative stress-induced inflammation³² and also in recruiting NK cells in a viral
308 response³³. EGLN1/PHD2 and SERPINB8 are involved in anti-inflammatory roles^{34,35}. At day
309 35, we found relatively fewer changes (Supplementary Figure 5C). Altogether, differences in
310 plasma proteome dynamics in TRs and NRs highlights the differential response to
311 vaccination induced in the two groups.

312

313 We also assessed untargeted metabolomic data measured by liquid chromatography-gas
314 spectrometry (LC-MS) and focused specifically on 192 endogenous metabolites (see
315 Methods). No significant differentially abundant metabolites between TRs and NRs were
316 found, irrespective of the time points. However, metabolites in TRs showed significant
317 changes at day seven and 35 compared to pre-vaccination, whereas this was less evident in
318 NRs (Figure 3C top, Supplementary Data 5). Summarising the metabolites into taxonomic
319 classes, TRs showed significant increased abundance of organic acids, particularly amino
320 acids, crucial for adequate immune function both at seven and 35 days post-vaccination¹⁴.
321 On the other hand, metabolites with reduced abundance both at seven and 35 days post-
322 vaccination were lipids and lipid-like molecules, more specifically fatty acyls (Figure 3C
323 bottom, Supplementary Figure 5D, 5F). These findings were validated in the replication
324 cohort, suggesting that overlapping metabolic signatures were induced by vaccination in
325 both seasons (Supplementary Figure 5E). Interestingly, four out of five upregulated lipids
326 and lipid-like molecules in TRs are bile acids. Bile acid perturbation has been described in
327 antibiotics-treated donors with low antibody response to vaccination¹². In contrast, NRs did
328 not show any significant differences in metabolite abundance seven days post-vaccination,
329 but instead showed a decrease in lipid abundance 35 days post-vaccination (Figure 3C top
330 and bottom). Pathway over-representation analysis in TRs at day seven showed significant
331 upregulation of metabolic pathways involving amino acid, glycine/serine metabolism and
332 glucose homeostasis (Figure 3E, Supplementary Data 6). On the other hand, downregulated
333 metabolic pathways were related to fatty acids, linoleic acid metabolism and signal
334 transduction, among others. In summary, the increased and sustained abundance of amino

335 acids with reduced abundance of fatty acyls over time suggests the importance of these
336 metabolite classes in vaccine response.

337

338 Furthermore, we integrated plasma molecules upregulated at day seven with transcriptome
339 BTMs to derive their functional significance. In TRs, protein concentrations of TNFRSF13B
340 and IFNLR1 were strongly positively associated with B cells and plasma cell immunoglobulin
341 modules from transcriptome (False Discovery Rate (FDR) <0.05). The CCL3, GZMA and
342 CD48 protein concentrations were also significantly positively associated with T cell
343 transcriptional modules, suggesting their role in the activation of T cells. Among metabolites,
344 uridine and tyrosine also showed positive associations with T cell activation and plasma cell
345 numbers, which may imply their involvement in mounting the immune response. Uridine has
346 previously been shown to be important for T cell proliferation³⁶. Beta-alanine, lactic acid and
347 serine all positively correlated with NK cells (Figure 3F). In contrast, no significant
348 associations between the proteome and transcriptional modules were found in NRs.
349 However, EGLN/PHD2, SERPINB8 and NBN were negatively associated with inflammatory
350 pathways (nominal p-value < 0.05, Supplementary Figure 6). Combining these results, we
351 show distinct changes in the proteome and metabolome following vaccination and describe
352 their potential significance in shaping the vaccination response in the elderly vaccine
353 responders.

354

355

356 ***Multi-omics integration reveals a common axis of variation across layers separating*** 357 ***high and low responders***

358

359 Next, we integrated the three omics layers of the highest (TRs, n=10) and lowest responders
360 (NRs, n=10) to examine the interconnected processes underlying the heterogeneous
361 influenza vaccine response in the elderly. Using multi-omics factor analysis (MOFA)³⁷, an
362 unsupervised method, 15 latent factors were identified which explained different levels of
363 data variation along with varying contributions of omics layers within each latent factor
364 (Figure 4A). Among these, factor three showed a common axis of variation among three
365 omics layers that separated TRs from NRs irrespective of time (Figure 4B). Examining
366 significance of the other factors showed that factors four and six were consistent with the
367 time dynamics differences observed in TRs and NRs (Supplementary Figure 7A).

368

369 To examine the significance of this common axis (latent factor three), we examined the top
370 proteins and metabolites identified through this factor (Figure 4C) and evaluated these in all
371 TRs (n=71) and NRs (n=10). Among the proteins, CCL25 and CCL3 were consistently more
372 abundant in TRs than in NRs. Similarly, for metabolites, the amino acids arginine and
373 methionine were more abundant in TRs (Figure 4D and Supplementary Figure 7B). To
374 further assess the significance of these amino acids in immune function, we examined the
375 association of amino acids with cytokine production capacity, particularly induced upon
376 influenza stimulation in an independent cohort of 500 healthy individuals^{38,39}. Arginine and
377 methionine showed significant positive associations with IL1 β , IL6 and TNF α (Figure 4E,
378 Supplementary Figure 7C). The increased abundance of these amino acids in TRs and their
379 positive association to pro-inflammatory cytokine production may indicate their involvement
380 in shaping the adaptive immune response to influenza vaccination via modulation of cytokine
381 production.

382

383 Finally, we then created a network of significant intra- and inter-omic connections by
384 associating plasma molecules with transcriptome BTMs (Methods), overlaying the weights
385 assigned for TRs (red) and NRs (blue) from MOFA latent factor three (Figure 4E). Across
386 omic layers, the transcriptome and proteome were highly connected, whereas the
387 metabolome was less connected to the other two layers. The metabolite arginine was
388 positively associated with TR-related BTMs involving plasma cells and immunoglobulins.
389 Similarly, xanthosine was positively associated with immune activation BTMs, which was
390 estimated as a predictor for NRs. Both xanthosine and orotidine are involved in nucleotide
391 metabolism which plays an important role in inflammation^{40,41}. We also observed strong
392 positive associations of glyceric acid 1,3-bisphosphate/1,3-BPG with up to seven proteins
393 that are predictors for NRs. In summary, we describe a common axis of variation in
394 transcriptome, proteome and metabolome which highlights the interconnected differences in
395 influenza vaccine response between elderly TRs and NRs.

396
397

398 ***Pre-vaccination high plasma IL-15 concentration negatively correlates with antibody*** 399 ***response***

400

401 One of the prerequisites for complete protection is the ability to produce sufficient antibodies
402 against all three strains of the influenza vaccine. To prioritise the important pre-vaccination
403 plasma proteins for antibody response to three strains of influenza vaccine concurrently, we
404 used partial least square regression (PLSR) in 200 donors (discovery cohort). This allowed
405 us to perform a systematic investigation of heterogeneity at the pre-vaccination time point.
406 The resulting proteins from the top three PLSR components explain ~40% variance of the
407 antibody fold change within the cohort (Figure 5A). We evaluated the top 30 proteins from
408 each of the three components to examine the directionality of the association with antibody
409 response per strain (Figure 5B). Overall, the majority of the prioritised proteins showed
410 contrasting associations with the three strains. Interestingly, TNFSF13/APRIL and IL-15
411 were negatively associated with antibody fold changes for all three strains (Figure 5B,5C and
412 Supplementary Figure 8A left). Both these proteins have been described as pro-
413 inflammatory cytokines and in the pathogenesis of influenza infection⁴²⁻⁴⁴. In the replication
414 cohort, we also found IL-15 negatively associated with high antibody changes for two strains,
415 whereas this was not true for TNFSF13, perhaps due to the small effect size that is hard to
416 replicate in a smaller cohort (Supplementary Figure 8A right, 8B). Single-cell RNA
417 sequencing on human PBMCs showed that IL-15 is mainly expressed by monocytes⁴⁵
418 (Supplementary Figure 8C). Based on these results, the contrasting relationship of the
419 majority of prioritised proteins against the three strains suggests a complex relationship of
420 these proteins involved in providing complete protection against influenza infection.
421 However, the consistent negative association of IL-15 with antibody response in both the
422 discovery and replication cohort suggests a detrimental role in protection against influenza.

423
424

425 ***High IL-15 concentration leads to reduced antibody titres through NK cells mediated*** 426 ***suppression of germinal centre responses***

427

428 IL-15 is important for NK cell proliferation and maturation⁴⁶⁻⁴⁸. From both bulk and previously
429 reported single-cell transcriptomics⁷, we observed higher frequencies of activated NK cells
430 and total NK cell numbers in NRs (Figure 1E). NK cells have been described to suppress

431 germinal centre (GC) responses^{49,50}. We therefore examined the impact of a perturbation of
432 the IL-15-NK cell axis on antibody production with *IL15RA*-deficient mice. We immunised
433 *IL15RA*^{+/+} and *IL15RA*^{-/-} mice with ovalbumin (OVA-IFA or OVA-Alum) to examine the
434 resulting humoral response 11 days post-immunization, at the time of maximum GC-
435 response in this animal model⁵¹ (Figure 5D). *IL15RA*^{-/-} mice showed a marked reduction of
436 NK cells in the spleen (as anticipated, given the importance of IL-15 for NK cell numbers),
437 without significant differences on B cell populations, but with slight differences on the
438 frequency of CD4+ and CD8+ T cells (a population that can also be affected by IL-15
439 reduction) (Figure 5E, Supplementary Figure 9A). In the draining lymph node, we observed a
440 consistent increase of Tfh cells and a decrease of Treg and Tfr cells in *IL15RA*^{-/-} mice,
441 although without reaching statistical significance (p-values > 0.05) (Supplementary Figure
442 9B). However, the Tfh/Tfr ratio, critical in the regulation of GC responses⁵², was significantly
443 higher in *IL15RA*^{-/-} mice (p-value = 0.02, Wilcoxon ranked sum-test, Figure 5F). In the same
444 mice that had an increased Tfh/Tfr ratio, we observed higher production of antibodies,
445 across two different immunisation protocols (p-values = 0.006 (OVA-Alum) and 0.048 (OVA-
446 IFA), Wilcoxon ranked-sum test, Figure 5G-H). In conclusion, these results suggest that the
447 reduction of IL-15 and NK cells led to more effective antibody production, in line with the
448 data from elderly NRs who displayed higher IL-15 and NK cell activation together with poor
449 antibody response (Figure 5I).

450

451

452 ***Pre-vaccination plasma malic and citric acid concentrations negatively correlate with*** 453 ***antibody response***

454

455 To evaluate the pre-vaccination metabolite levels with antibody responses against three
456 strains, PLSR was used in a similar way as described above. Herein, the metabolites in the
457 top eight PLSR components explain ~40% variation of the antibody fold change among
458 donors suggesting high inter-individual variation in the donors as a consequence of
459 metabolic differences (Figure 6A). Metabolites prioritised in the first component showed
460 malic acid and citric acid as top molecules, with negative associations to antibody response
461 (Figure 6B, 6C and Supplementary Figure 9A). To derive the role of citric acid and malic acid
462 in immune function, we associated pre-vaccination abundance of these metabolites with
463 deeply phenotyped immune cell counts and cytokine production induced upon influenza
464 stimulation in two independent cohorts of 300 and 500 healthy individuals,
465 respectively^{38,39,53,54}. Citric acid showed significant negative associations with
466 CD4+CCR6+CCR5+CCR7+ T cells along with three different subsets of immature
467 neutrophils (FDR<0.05) (Supplementary Figure 9B). Malic acid showed strong negative
468 associations with TNF α , IL6 and IL1 β cytokine levels upon influenza stimulation (Figure 6D).
469 Furthermore, we found betaine and cysteine as the top predictors from components one and
470 two, respectively, to be consistently positively associated with antibody response across all
471 strains (Figure 6B and Supplementary Figure 9C). Betaine has been described for its
472 inhibition of IL1 β production and release^{55,56} and for its suppression of pro-inflammatory
473 signalling during ageing⁵⁷. These results reflect the impact of pre-vaccination metabolite
474 abundance linked to different physiological immune states across responders culminating in
475 differential vaccination response in the elderly.

476

477

478 ***Unsaturated long chain fatty acids are negatively associated with pre-vaccination IL-***
479 ***15 abundance***

480

481 Given the putative role of high IL-15 in suppressing antibody production in the elderly, we
482 evaluated the relationship of pre-vaccination IL-15 abundance and metabolites. Pre-
483 vaccination IL-15 showed strong negative associations with odd-chain (pentadecanoic acid)
484 and certain unsaturated long-chain fatty acids (LCFAs, e.g. palmitoleic acid) (p value < 0.02)
485 (Figure 6F and Supplementary Figure 9D). These LCFAs were also among the top 30
486 predictors for PLSR component two, explaining variation in antibody fold change among the
487 donors (Figure 6E and 6F). LCFAs and especially poly-unsaturated fatty acids have been
488 described as important immunomodulatory metabolites to protect against infections⁵⁸. To
489 test the significance particularly of LCFAs in suppressing inflammatory proteins, the
490 relationship of all pre-vaccination lipid and lipid-like molecules (taxonomy class) with these
491 proteins was examined. LCFAs were negatively associated with inflammatory proteins,
492 whereas other lipid molecules showed both positive and negative associations
493 (Supplementary Figure 9E). We also examined the role of LCFA in a younger cohort
494 (500FG^{38,39}, with 98% donors less than 65 years of age), however, the LCFA-specific
495 negative associations with inflammatory proteins were absent (Supplementary Figure 9E).
496 Among the LCFAs, the most significantly negatively associated metabolite was
497 pentadecanoic acid, an odd-chain fatty acid with anti-inflammatory properties and resistance
498 to oxidation^{59,60}. Taken together, the data suggests an age-dependent role of LCFAs in the
499 control of inflammation. We described different metabolites associated with IL-15 and other
500 inflammatory proteins, as well as the antibody fold change, suggesting their role in
501 modulating the vaccine response in the elderly, particularly LCFAs as potential pre-
502 vaccination suppressors of high inflammation.

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573

DISCUSSION

In this work, we evaluated a large cohort of healthy elderly individuals to understand the heterogeneity of influenza vaccination response, specifically to address two main questions: 1) How does the vaccination response differ between responders and non-responders, and 2) Which pre-vaccination biomarkers correlate with the vaccination response. To answer these questions, we examined the transcriptome, proteome and untargeted metabolome of these donors separately, as well as across omics layers.

In the transcriptome, proteome, and metabolome layers, we observed post-vaccination dynamics that were indicative of mounting of an immune response to vaccination in TRs whereas, as expected, these dynamics were absent or altered in NRs. NRs were instead characterised by increased and activated NK cell populations and persistent inflammation. In line with these findings, the NK cell receptor *KLRB1* was shown as a negative predictor for vaccine response in the elderly²¹, whereas *NKG2C* expression was reported as positively correlated with influenza vaccination⁶¹ in healthy individuals. This opposing observation of NK cells may be related to the ageing immune system. Signalling through inflammatory molecules is important for mounting an immune response, while persistent low-grade inflammation, termed ‘inflammaging’, can result in exhaustion and is detrimental to the vaccine response^{62,63}. In NRs, evidence from the transcriptome suggests persistent inflammation driven through AP-1 transcriptional networks, among others. On the other hand, the post-vaccination proteins consist of proteins with anti-inflammatory roles. These opposing findings from the different layers may suggest a dysregulation where NRs are attempting to suppress the inflammation resulting from vaccination required for mounting the necessary immune response. A recent study has revealed endotypes predictive of antibody response to vaccination across different vaccines, including influenza¹³. However, this endotype was not identified in elderly (>50 years) individuals. Our study extends these findings in the elderly and defines the pre-vaccination transcriptome profile separating high and low responders, with adaptive immune modules enriched in high responders. This suggests that a high persistent inflammatory status predictive of high responders in the young is increasingly detrimental with age.

Using multi-omics integration for day seven and across time points, we were able to find key molecules that are important in supporting and leading to a productive vaccine response. Interestingly, some of these identified molecules e.g. CCL25, CCL3 and arginine have

574 already been studied as potential immune-adjuvants in vaccination and/or as
575 supplementation for a better humoral response to vaccination^{31,63-65}. CCL25, a chemokine
576 ligand for CCR9 has been shown to play both pro and anti-inflammatory roles in various
577 diseases⁶⁶. CCL3 and its receptor CCR5 have been implicated in leukocyte recruitment into
578 the airway leading to upregulation of antiviral responses in influenza infection⁶⁷. Amino acids
579 in general are crucial for immune function^{14,15}. In fact, we observed consistent upregulation
580 of amino acids post-vaccination in TRs, but not in NRs. In this study, we showed functional
581 associations of plasma concentrations of metabolites arginine and methionine to cytokine
582 production upon influenza stimulation using an independent cohort. The upregulation of
583 these amino acids in TRs irrespective of vaccination and the role of these molecules in
584 cytokine production suggests an important role in protective immunity and consequently
585 markers of protection in elderly TRs. In summary, we indicate biomarkers that support both a
586 robust immune response to influenza stimulation and the vaccine response.

587
588 Pre-vaccination plasma IL-15, malic acid, and citric acid concentrations are negatively
589 associated with antibody response. We propose a model where high abundance of pre-
590 vaccination IL-15 leads to increased activated NK cells, which in turn inhibit the GCs to
591 suppress antibody production (Figure 6F). Modulation of adaptive immune responses
592 through NK cells has been proposed for better vaccine design, where NK cells control the
593 magnitude and quality of immune response⁶⁸⁻⁷⁰. Previous work and our current results have
594 shown lower levels of T and B cells in NRs compared to TRs⁷. The simultaneous decrease
595 of T and B cells, with increased NK cell proportions may further cause the suppression of
596 antibody responses in NRs. Monocytes are the main source of IL-15 in immune cell
597 populations in human blood and are reported to produce more IL-15 with increasing age⁷¹.
598 We did not observe higher monocyte proportions but higher monocyte (inflammatory)
599 transcriptional activity in NRs. IL-15 has also been described to inhibit apoptosis of
600 neutrophils⁷², which were more abundant in our NRs.

601
602 Together, these findings suggest contributions from inflammatory monocytes and neutrophils
603 in maintaining a persistent inflammatory milieu in NRs. The receptor for IL-15 is also
604 expressed by dendritic cells and the importance of the cross-talk between NK cells and
605 dendritic cells in immune cell activation and maturation has been established⁷³. We did not
606 observe differences in deconvoluted dendritic cell proportions between TRs and NRs.
607 However, cross-talk between these cell subsets within the secondary lymphoid tissues could
608 play a role during influenza infection and its role in vaccination in the elderly is of interest for
609 future research. The top predictors from the metabolome PLSR component two consisted of
610 methionine and fatty acids, particularly unsaturated LCFAs. Methionine was one of the top
611 predictors for TRs picked by MOFA, as well as one of the top metabolites upregulated at day
612 seven post vaccination in TRs. Interestingly, unsaturated LCFAs were all negatively
613 associated with IL-15. Recent work has highlighted the role of fatty acid metabolism in the
614 IgG1 response to influenza¹². In line with this, we observed consistent downregulation of
615 fatty acyls in TRs post-vaccination, whereas this only occurred in NRs at the later time point
616 (day 35). These findings suggest a multifaceted role of fatty acyls by serving as energy
617 molecules and/or signalling molecules, thereby modulating the immune response.
618 Metabolites with known anti-inflammatory properties such as (poly)-unsaturated LCFAs and
619 odd-chain fatty acids could alleviate the chronic inflammation, leading to a more productive
620 vaccination response in the elderly.

621

622 We also need to acknowledge the limitations of this study. Larger cohorts are required in
623 future studies to fully explore the molecular mechanisms leading to a protective or
624 detrimental vaccine response. This includes examining the role of genetics in interindividual
625 variation, the host microbiome and its interactions with the metabolome. The role of
626 comorbidities frequently observed in the elderly (type 2 diabetes, cardiovascular diseases,
627 etc.) may also affect the response to vaccination. Indeed, we found that a history of diabetes
628 or herpes zoster (shingles) were independent risk factors for a poor humoral immune
629 response to the H1N1 vaccine antigen in this study cohort¹⁹. Furthermore, it was recently
630 identified in a study of responsiveness to COVID-19 vaccination that comorbidities, such as
631 diabetes, are associated with a pro-inflammatory response and reduced vaccine
632 responsiveness^{74,75}. Although “inflammaging” associated with pro-inflammatory cytokines is
633 also emerging as a common feature of poor vaccine responsiveness in people with chronic
634 diseases and old age, it will be critical to understand the potential universal character of the
635 identified mechanisms and biomarkers by performing studies using other vaccines and
636 populations. Therefore, future studies incorporating these factors will provide an improved
637 understanding of the vaccine response in the elderly. Furthermore, *in vivo* experiments and
638 clinical trials are required to assess whether modulation of metabolites can improve the
639 vaccine response in (elderly) non-responders.

640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669

670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716

ACKNOWLEDGEMENTS & FUNDING

The authors thank all the participants in this study. We thank the Research Core Unit Metabolomics of the Hannover Medical School for supporting the targeted metabolomics measurements. This work was supported by an ERC starting Grant (948207), a Radboud University Medical Centre Hypatia Grant (2018) and the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) under Germany's Excellence Strategy - EXC 2155 project number 390874280 to YL and iMed, the Helmholtz Association's Cross Programme Initiative on Personalized Medicine, to CAG and FP. C-JX was supported by a Helmholtz Initiative and Networking Fund (1800167). MGN was supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. LG research was supported by grants HR22-00741 ("la Caixa" Foundation), and 2022.04903.PTDC (Fundação para a Ciência e Tecnologia Portugal). This project was also partly supported by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 955321

AUTHOR CONTRIBUTIONS

Conceptualization and study design: YL
Sample collection: ST, PR, FP, CAG
Sample preparation: LZ, AA
Data analysis and investigation: SK, MZ, NN.
Murine experiments: RP, LG
Discussion and interpretation: SK, MZ, ST, PR, JBB, CJX, LABJ, MGN, LG, CAG, FP, YL
Writing - original manuscript: SK, MZ, JBB, CJX, YL
Reviewing and editing manuscript: All authors.

DECLARATION OF INTERESTS

The authors declare no competing interests

DATA AND CODE AVAILABILITY

717 Raw data and code will be made available upon publication. Datasets are fully available for
718 reviewers.

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733 **FIGURE LEGENDS**

734

735 **Figure 1.** *Influenza vaccination cohort overview and transcriptome of highest and lowest*
736 *responders. (A).* Overview of the different omics datasets generated in this study. We
737 generated multi-modal datasets covering the transcriptome, proteome and metabolome
738 response to influenza vaccination from up to 234 individuals for different timepoints spanning
739 both pre and post-vaccination, covering two independent seasons of influenza vaccination.
740 The serological data is adapted from earlier publications on the same cohort^{7,17} **(B).** Circos
741 plot showing the serological response to trivalent inactivated influenza vaccine (TIV). Each
742 heatmap depicts pre-vaccination antibody titres against the particular strains included in the
743 vaccine (H3N2, H1N1, B), whereas the corresponding histograms show the log₂ fold-change
744 in antibody titres against the strains upon vaccination. Donors were classified as TR, NR or
745 Other based on their serological response (outer tiles). **(C)** Heatmap showing mean gene
746 expression levels across 10 TRs and 10 NRs for each time point. Each row is a gene that is
747 significantly differentially expressed between TRs and NRs, with purple indicating higher
748 gene expression levels and green indicating lower gene expression levels (adj. p-value <
749 0.01). **(D)** Top 40 BTMs listed based on gene set enrichment analysis (GSEA) of genes that
750 are differentially expressed between TRs and NRs. Positive (red) normalised enrichment
751 scores (NES) correspond to BTMs upregulated in TRs, whereas negative NES corresponds
752 to BTMs upregulated in NRs. **(E)** Line plots depicting immune cell population proportions for
753 all timepoints as estimated by CIBERSORT, stratified for TRs and NRs. Each dot is a
754 sample coloured for TRs (red) or NRs (blue).

755

756 **Figure 2.** *Low inflammatory status at pre-vaccination stage indicator of high responders. (A)*
757 *BTMs significantly upregulated in TRs at the pre-vaccination timepoint. Boxplots show*
758 *median with interquartile range and Tukey whiskers. (B)* Line plot summarising changing
759 gene expression in TRs (red) and NRs (blue) upon vaccination indicated by the percentage
760 of significantly differentially expressed genes over time compared to pre-vaccination. **(C)**
761 Line plots for two clusters of genes, where the cluster "Transient day 3 TRs" contains genes
762 upregulated in TRs at day 3 post-vaccination. Genes in the cluster "consistent up NRs" are
763 upregulated in NRs at all timepoints. Each dot represents the mean of genes per donor for
764 each cluster, line plot stratified for TR and NRs. **(D)** Mean expression of genes for significant

765 BTMs and HALLMARK pathways clustered shows split based on transient upregulation in
766 TRs (top) and downregulation in TRs at all time points (bottom). **(E)** Association of
767 CIBERSORT cell proportions with cell cycle BTMs (left) and cell type signature BTMs (right)
768 at seven days post-vaccination. Size of the dots represent adjusted p-values from linear
769 mixed models, whereas colour represents the estimate from the model. Associations with
770 adjusted p-values < 0.05 plotted, for TRs, while all associations for NRs with cell cycle BTMs
771 only irrespective of adjusted p-value threshold (grey). Associations with adj. p-value < 0.05
772 for cell type signature BTMs for NRs shown.

773

774 **Figure 3** *Plasma proteins and metabolite changes upon vaccination are distinct in TRs and*
775 *NRs. (A)* Line plot showing significant changes (padj < 0.05) in protein abundance in TRs (N
776 = 71) and NRs (N=10) post-vaccination. TRs show a higher percentage of significantly
777 regulated proteins, while NRs show a comparably dampened response. **(B)** Volcano plot of
778 proteins upregulated in TRs and NRs 7 days post vaccination with significant proteins
779 coloured in red and labelled; Proteins were considered significant at adj. p-value < 0.05 **(C)**
780 Line plot showing significant changes in metabolite abundance in TRs (N=71) and NRs
781 (N=10) post vaccination. **(D)** Significantly differentially regulated metabolites categorised
782 based on their taxonomic class as annotated by the Human Metabolome Database (HMDB).
783 The upper and lower parts of the bars represent up- and down regulated metabolites,
784 respectively. The "Measured" column represents the total universe of metabolites that we
785 considered (192 endogenous metabolites, see Methods). The TR and NR columns indicate
786 significantly regulated metabolites at each timepoint compared to day 0. **(E)** Pathways
787 enriched for metabolites with increased or decreased abundance 7 days post vaccination in
788 TRs. Enrichment of pathways was calculated using IMPALA. Pathways with adj. p-value <
789 0.05 are shown. **(F)** Integration of proteins and metabolites with increased abundance at 7
790 days post vaccination with transcriptome pathways in TRs. Linear mixed models were used
791 to estimate the association between protein / metabolite abundance and mean
792 transcriptomic pathway activity (Methods). Drawn links are significant with adj. p-value <
793 0.05. Colour and width for the links are based on p-values, where wide red links indicate
794 increased significance.

795

796 **Figure 4** *Multiomics integration of high and low responders (A)* Bar plot showing the
797 proportion of explained variance per factor resulting from unsupervised factor analysis
798 method MOFA. Colours within each bar indicate the contribution of each modality. **(B)** MOFA
799 Factor 3 separates TRs from NRs irrespective of time and across modalities. Y-axis
800 represents the Factor 3 variance value attributed to each donor. P-values are generated
801 using a Wilcoxon ranked-sum test. **(C)** Top most positive and negative molecules within the
802 metabolome and proteome modalities as calculated by MOFA. Molecules are ranked on
803 MOFA scaled weights for factor 3. Positive weights are for TRs, whereas negative weights
804 correspond to NRs. **(D)** Abundance of CCL25 and L- arginine in all 81 TR and NRs. P-values
805 are generated using a Wilcoxon ranked-sum test. **(E)** Association of arginine with cytokine
806 response post influenza stimulation in 500 FG cohorts. P-values are generated using t-test.
807 Partial correlation estimate was calculated, corrected for age and gender **(F)** Integrative
808 network of transcriptome, proteome and metabolome data. Nodes in the network correspond
809 to molecules (proteome, metabolome) or BTMs (transcriptome). Only molecules and
810 pathways identified by MOFA weights (Supplementary Figure 6F) are plotted. Edges in the
811 network (all adj. p-value < 0.05) are statistical associations from linear mixed models (see

812 Methods), where red edges represent positive associations and blue edges represent
813 negative associations.

814

815 **Figure 5** *Pre-vaccination plasma proteome correlates to the antibody response to*
816 *vaccination (A)* Proportion of co-variation in proteome and antibody fold change explained by
817 each component for either each strain or the predictors examined through PLSR analysis
818 with 10-fold cross validations (N = 200). The first three components using the predictors
819 were able to explain ~ 40% co-variation in the antibody response and pre-vaccination protein
820 abundance **(B)** Heatmap of t-test statistics for top predictors with antibody fold change for
821 top three components as calculated using rank product analysis for these components. Most
822 proteins show heterogenous associations with the antibody fold change against the three
823 influenza strains, with notable exceptions for IL-15 and TNFSF13 in component 1. **(C)**
824 Correlation plots of IL-15 against antibody fold change for all 200 donors. **(D)** $IL15RA^{+/+}$ and
825 $IL15RA^{-/-}$ mice were immunised with OVA-Alum or OVA-IFA in the footpad, followed by
826 analysis of antibody titres, and lymphocyte populations from inguinal lymph nodes 11 days
827 post-immunization. **(E)** Proportion of B (CD19+), T (CD3+), NK (NK1.1+) cells, as well as
828 CD4+ and CD8+ T cell subsets, among splenocytes of unimmunized $IL15RA^{+/+}$ and $IL15RA^{-/-}$
829 mice. **(F)** Ratio of Tfh/Tfr cells, calculated from their frequency among total CD4+ cells,
830 within LNs of immunized $IL15RA^{+/+}$ and $IL15RA^{-/-}$ mice. **(G)** Serum concentration of OVA-
831 specific IgG1 in mice immunized with OVA-alum, or **(H)** immunized with OVA-IFA. **(I)**
832 Schematic summarising the mechanism of IL-15-mediated activation of NK cells leading to
833 suppression of germinal centre responses and low production of antibodies.

834

835 **Figure 6** *Pre-vaccination plasma metabolites as modulators for vaccination response (A)*
836 Proportion of co-variation in endogenous metabolites and antibody fold change explained by
837 each component for either each strain or the predictors examined through PLSR analysis
838 with 10-fold cross validations (N = 200). The first 8 components were able to explain ~ 40%
839 co-variation in the antibody response and pre-vaccination metabolite abundance **(B)** Plot of
840 metabolites from component 1 with their ranks and estimated percentage of false predictions
841 (PFP) (left), Heatmap of t-test statistic for the top predictors with antibody fold change for the
842 top component as calculated using rank product analysis for these components (right). Most
843 metabolites show heterogeneous associations to the different influenza strains in the
844 vaccine, except for malic acid and citric acid showing negative association while betaine
845 shows positive association. **(C)** Correlation plots of malic acid against antibody fold change
846 for all three influenza strains for all 200 donors. **(D)** Association of malic acid to cytokine
847 production upon influenza stimulation in an independent cohort of 500 younger healthy
848 individuals, showing a negative trend. P-values are generated using t-test. Partial correlation
849 estimate was calculated, corrected for age and gender **(E)** Top metabolites for component 2
850 with their ranks and estimated percentage of false predictions shows long chain fatty acids
851 as top candidates. **(F)** Negative association of these long chain fatty acids identified in PLSR
852 component 2 with IL-15. P-values are generated using t-test. Partial correlation estimate was
853 calculated, corrected for age and gender **(G)** Schematic describing the role of IL-15 in
854 delayed neutrophil apoptosis, maturation and activation of NK cell populations, leading to
855 suppression of GC responses and reduced antibody production and a chronic inflammatory
856 status. Evidence for each observation is derived through different omics layers and
857 experiments. Connections among different observations were also supported by published
858 findings.

859

860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879

880 **METHODS**

881

882 *Study population*

883

884 The study population has been described before in detail by Riese, Akmatov and
885 colleagues^{7,17}. Briefly, a prospective population-based study across two Influenza seasons
886 (2014/2015 and 2015/2016) was performed among elderly individuals (>65 years of age)
887 from Hannover, Germany. Donors from both seasons did not overlap. Participants were
888 recruited from a random sample from the local population registry and represented the
889 general population as verified by a survey¹⁸. Intravenous blood samples were drawn before
890 vaccination (day 0) and on day 1, day 3, day 6/7, day 21 & day 70 post-vaccination.
891 Hemagglutination inhibition titres and microneutralization titres were measured as described
892 before⁷. Briefly, we followed the formulation of the Fluvad vaccine and used the following
893 antigens for titre measurements in serum: H1N1 A/California/7/09 NYMC-X181 (both
894 seasons), H3N2 A/Texas/50/2012 NYMC-223 (season 2014/2015), H3N2
895 A/Switzerland/9715293/2013 NIB88 (season 2015/2016), B/Massachusetts/02/2012 NYMC
896 BX-51B (season 2014/2015) and B\Brisbane/9/2014 (season 2015/2016). Sero-conversion
897 was defined as either a post-vaccination titre of ≥ 40 for individuals with pre-vaccination titres
898 < 10 , or a 4-fold increase in titre upon vaccination for individuals with pre-vaccination titre
899 ≥ 10 . Individuals were classified as Triple Responders (TR, sero-conversion against all three
900 strains), Non-Responders (NR, no sero-conversion against any strain), or Other (sero-
901 conversion against at least one strain but not all three).

901

902 *Bulk transcriptome sequencing*

903

904 Bulk transcriptome sequencing has been described before⁷. In short, ten TRs and ten NRs
905 were selected based on their serological response to vaccination. We included five time
906 points per individual: baseline, day 1/3, day 6/7, day 21/35 & day 60/70. miRNA and total
907 RNA were purified from whole blood samples frozen in PAXgene™ tubes (BD) using the
“PAXgene Blood miRNA Kit” (Qiagen). The detailed procedure was previously described⁷.

908

909 *Untargeted metabolomics*

910 We assessed the metabolic profiles of 702 individuals from two influenza seasons. Plasma
911 samples were randomised across plates with respect to vaccine response, sampling time
912 point and sex. Polar metabolites were extracted from each sample with 180 μ L 80%
913 methanol in a deep well extraction plate using 20 μ L plasma by General Metabolics, Boston,
914 USA. Samples were vortexed for 15 seconds, incubated at 4°C for one hour and centrifuged
915 at 4°C, 3750 RPM for 30 minutes. Metabolome profiles of the sample extracts were acquired
916 using flow-injection mass spectrometry. The method described here is adapted from
917 previously described methods⁷⁶. The instrumentation consisted of an Agilent 6550 iFunnel
918 LC-MS Q-TOF mass spectrometer in tandem with an MPS3 autosampler (Gerstel) and an
919 Agilent 1260 Infinity II quaternary pump. The running buffer was 60% isopropanol in water
920 (v/v) buffered with 1 mM ammonium fluoride. Hexakis (1H, 1H, 3H-tetrafluoropropoxy)-
921 phosphazene (Agilent) and 3-amino-1-propanesulfonic acid (HOT) (Sigma Aldrich). The
922 isocratic flow rate was set to 0.150 mL/min. The instrument was run in 4GHz High
923 Resolution, negative ionization mode. Mass spectra between 50 and 1,000 m/z were
924 collected in profile mode. 5 μ L of each sample were injected twice, consecutively, within 0.96
925 minutes to serve as technical replicates. The pooled study sample was injected periodically
926 throughout the batch. Samples were acquired randomly within plates.

927

928 *Targeted metabolomics*

929 Serum concentrations of amino acids were determined by mass spectrometry, using an
930 HPLC-coupled triple quadrupole mass spectrometer (AP4000, Siex) and the AbsoluteIDQ
931 p180 kit (Biocrates Life Science AG, Innsbruck, Austria) following the manufacturer's
932 protocols⁷⁷.

933

934 *Targeted proteomics*

935 We measured 384 circulating proteins in plasma using Olink's proximity extension assay
936 (PEA) Explore Inflammation panel⁷⁸ in 702 individuals. In the PEA, oligonucleotide-labelled
937 antibodies ("probes") bind the protein of interest. Linking of the probes is triggered by close
938 proximity of two antibodies which limits cross-reactivity. Upon linking, the probe sequence is
939 hybridised and subject to extension by DNA polymerases. The resulting sequence is
940 quantified by real-time polymerase chain reaction. Protein values are expressed as
941 normalised protein expression (NPX) values, a relative value on a log₂ scale. Quality control
942 of the raw data was performed by Olink (incubation controls, extension controls and
943 detection controls).

944

945 *Immunisation, cell isolation and blood serum collection of IL15RA^{-/-} and IL15RA^{+/+} mice*

946 Sex-matched IL15RA^{-/-} and IL15RA^{+/+} C57BL/6 mice, aged from 10 to 12 weeks, were
947 immunized in the back paw footpad with Ovalbumin (OVA, Ovalbumin EndoFit, Invivogen,
948 #vac-pova) emulsified 1:1 (v:v) with either IFA (IFA, Sigma-Aldrich, #F5506) or Alum (Alu-
949 Gel-S, Serva, #12261-01). Each animal was inoculated with a volume of 50 μ L per paw
950 containing 80 μ g of OVA (OVA-IFA was injected in two paws while OVA-Alum was injected
951 in one paw per mouse). Mice were sacrificed 11 days after immunisation and the cells from
952 the spleen and inguinal lymph nodes (LNs) isolated. Blood serum from each mouse was also
953 collected at the same time point by cardiac puncture. The mice were bred and maintained
954 under specific pathogen-free conditions at the Instituto de Medicina Molecular (iMM), where
955 the experiments were performed under an animal experimentation authorization granted by

956 Direção-Geral de Alimentação e Veterinária (DGAV), the Portuguese national authority for
957 animal health, and iMM-ORBEA, the Ethic Committee for laboratory animal care at the iMM
958 Rodent Facility in Lisbon.

959 *Flow cytometry of IL15RA^{-/-} and IL15RA^{+/+} mice*

960 Characterization of the lymphoid cell populations in the spleen of IL15RA^{-/-} and IL15RA^{+/+}
961 C57BL/6 strains was done by flow cytometry with the following antibodies: anti-CD19-FITC
962 (MB19-1, eBioscience; 1:100), anti-CD3-APC (145-2C11, eBioscience; 1:100), anti-CD4-
963 BV510 (RM4-5, BioLegend; 1:400), anti-CD8-eF780 (53-6.7, eBioscience; 1:200), and anti-
964 NK1.1-PECy7 (PK136, eBioscience; 1:100). B and T cells subpopulations present in the
965 inguinal LNs were first pre-incubated with anti-CXCR5-Biotin (2G8, BD Biosciences; 1:50)
966 and subsequently stained with anti-CD19-FITC (MB19-1, eBioscience; 1:100), anti-CD95-PE
967 (Jo2, BD Biosciences; 1:100), anti-ICOS-PerCPCy5.5 (7E.17G9, BioLegend; 1:200), anti-
968 PD-1-PECy7 (J43, eBioscience; 1:100), anti-GL7-eF660 (GL-7, eBioscience; 1:100), anti-
969 CD25-APCeF780 (PC61.5, eBioscience; 1:200), anti-CD4-BV510 (RM4-5, BioLegend;
970 1:400), and anti-CD44-BV605 (IM7, BioLegend; 1:400) together with Streptavidin-BV711
971 (BioLegend; 1:100). Intracellular Foxp3 (FJK-16s, eBioscience; 1:100) staining was
972 performed using the Foxp3 Fix/Perm Kit (eBioscience, #00-5521-00) according to the
973 manufacturer's instructions. The samples were acquired on a BD LSRFortessa cytometer
974 from the iMM Flow Cytometry Facility and further analyzed on FlowJo software (TreeStar).

975

976 *Anti-OVA IgG quantification of IL15RA^{-/-} and IL15RA^{+/+} mice*

977 Serum anti-OVA mouse IgG1 was quantified by ELISA. 96-well plate wells were coated with
978 50 µl OVA (Ovalbumin EndoFit, Invivogen, #vac-pova) at 20 µg/ml in PBS overnight (4 °C),
979 washed 3 times with ELISA Buffer (Invitrogen, #88-50620-88) and subsequently blocked
980 with 200 µl of ELISA Buffer for at least 30 minutes. After washing, standards and different
981 dilutions of each serum sample were plated in duplicates in the coated wells for at least 90
982 minutes. The standard curve was obtained with measurements from known concentrations
983 of Anti-OVA [6C8] IgG1 antibody (AbCam, #ab17293). After washing, 50 µl of anti-mouse-
984 IgG1-HRP (SouthernBiotech, #1070-05) diluted 1:2000 were added to the wells and
985 incubated for at least 45 minutes. Wells were washed, and 50 µL of the substrate solution
986 3,3',5,5'-tetramethylbenzidine (TMB Single Solution, Life Technologies) were added per well.
987 The reaction was stopped with 25 µL of sulfuric acid (H₂SO₄) according to the colour
988 development of the standards. Lastly, optical density (OD) was read at 450 nm within 30
989 seconds after stopping the reaction. Quantification of Anti-OVA mouse IgG1 in each sample
990 of blood serum was attained by calculating the concentration of antibody considering the OD
991 values obtained for a dilution that fitted within the OD values of the standard curve (0.2 > OD
992 < 1).

993

994 *Flow cytometry of human PBMCs*

995 Cryopreserved PBMCs were thawed, rested for 2 h and incubated overnight with purified
996 anti-human CD28 and CD49d at a concentration of 10 µg/ml. For surface staining, cells were
997 incubated with the antibody mixture prepared in PBS for 30 min at 4°C in the dark. Cells
998 were stained for flow cytometric analysis using the following antibodies: CD3 (BUV395, SK7,
999 Cat.-No. 564001, dilution 1:200, BD (Franklin Lakes, New Jersey, USA)) and CD56 (BV785,
1000 5.1H11, Cat.-No. 362550, dilution 1:100, BioLegend (San Diego, USA)). The samples were

1001 acquired at a BD Fortessa flow cytometer using the Diva software and analyzed using
1002 FlowJo.

1003

1004 *Statistical analyses*

1005 *Bulk transcriptome analysis*

1006 We quantified bulk RNA sequencing data using Salmon⁷⁹ using default parameters and the
1007 human GRCh38 genome. To check for potential outliers, we performed principal component
1008 analysis (PCA). No samples were removed based on this analysis. We then imported the
1009 transcript-level quantifications and transcript lengths using tximport⁸⁰ and quantified the
1010 differential expression between responder groups and over time points using a limma-voom
1011 approach^{81,82}: $gene \sim responder + age + Time + sex + 1|donor$. For time dynamics, following
1012 linear model was used: $gene \sim responderTime + age + sex + 1|donor$. Functional enrichment
1013 was performed using gene set enrichment analysis (GSEA) using blood transcription
1014 modules (BTMs)²³. Genes were ranked by t-test statistic from this mixed linear model for the
1015 comparison of interest. P-values were adjusted using Benjamini-Hochberg, where we
1016 considered adj. p value < 0.01 significant or adj. p value < 0.05.

1017

1018 The relative contribution of individual cell types was estimated using CIBERSORT²⁴. using
1019 the LMM22 background. We defined the pathway activity as the mean expression corrected
1020 for variance across donors of all genes assigned to a specific BTM per sample. A linear
1021 model was used to associate the estimated proportions of individual cell types to functional
1022 pathways: $cell\ proportion \sim BTM_score + age + sex + 1|donor$, done separately for TRs and
1023 NRs. where *BTM_score* is the BTM score as described above and *cell proportion* is the
1024 estimated cellular proportions from CIBERSORT per individual. P-values were adjusted on
1025 all associations using Benhamini-Hochberg. We considered adj. p-values < 0.05 to be
1026 significant.

1027

1028 *Targeted proteomics*

1029 We removed measurements that were flagged as unreliable by Olink as well as protein
1030 assays where the target protein was detected in less than 70% of the samples. Finally, we
1031 considered 311 high-quality proteome assays for further downstream analyses. We
1032 performed dimensionality reduction (PCA) to check for potential outliers or batch effects and
1033 did not identify either.

1034

1035 To quantify the differences in protein abundances between timepoints within each responder
1036 group separately, we fit a linear mixed model using limma⁸¹: $protein \sim time_responder + age$
1037 $+ sex + 1|donor$, where *time_responder* indicates the sampling time point and responder
1038 group, and *donor* is the random effect. Benjamini-Hochberg post-hoc correction was used to
1039 control the false discovery rate across all proteins. We considered adjusted p-values < 0.05
1040 significant.

1041

1042 *Untargeted metabolomics*

1043 Raw metabolite profile data were centroided, merged and recalibrated using MATLAB
1044 software as previously described⁷⁶. Putative annotations were generated based on
1045 compounds contained in the HMDB⁸³ database using both accurate mass per charge and
1046 isotopic correlation patterns. We retained only ions that were confidently annotated, allowing
1047 0.001 Da tolerance between the ion and its corresponding annotation. Since exogenous

1048 and/or drug-related metabolites do not reflect an individual's current immune status and
1049 could lead to possibly confounding effects, we aimed to consider a set of endogenous
1050 metabolites. To do so, considered endogenous metabolites from HMDB and matched this to
1051 our annotated metabolite data based on the ion's chemical formula. Then, we manually re-
1052 checked whether metabolites were drug-related using the DrugBank database⁸⁴. Metabolites
1053 associated with medications or other xenobiotics were removed. Finally, we retained 192
1054 endogenous metabolites for further analyses.

1055
1056 We validated the quality of our untargeted metabolome data by using a targeted
1057 metabolomic approach on a subset of the individuals. We manually correlated 18 primary
1058 amino acids that were reliably detected and annotated between the two platforms and
1059 observed good replicability (median Pearson's $r = 0.77$). This indicates good sample quality
1060 and reliable, consistent measurements (Supplementary Figure 11).

1061
1062 We fit a linear mixed model in limma⁸¹ to quantify differences in endogenous metabolic
1063 abundances within responder groups over time: $metabolite \sim time_responder + age + sex +$
1064 $1|donor$, where $time_responder$ indicates the sampling time point and responder group, and
1065 $donor$ is the random effect. We applied Benjamini-Hochberg post-hoc correction on all
1066 endogenous metabolites and considered metabolites with adjusted p-values < 0.05
1067 significant. Metabolite classifications to annotate metabolites were retrieved from HMDB. We
1068 performed metabolite enrichment by performing over-representation analysis using
1069 IMPALA⁸⁵. Adjusted p-values (Benjamini-Hochberg) < 0.05 were considered significant.

1070 *Integration of transcriptome, proteome and metabolome layers*

1071
1072 We aimed to provide a comprehensive integration of the different data layers that were
1073 generated. To do so, we employed two approaches. First, we associated circulating protein
1074 and metabolite levels to transcriptome pathway activity. We defined pathway activity as
1075 described above. Proteins and metabolites were selected when differentially abundant at
1076 Day 7 compared to Day 0. Associations were estimated using a linear mixed model: $protein$
1077 $\sim age + gender + BTM + 1|donor$. P-values were adjusted using Benhamini-Hochberg over
1078 all obtained associations, and adjusted p-values < 0.05 were considered significant. We
1079 performed this analysis for Day 7 as we observe the peak of the adaptive immune response
1080 to vaccination on this day.

1081
1082 Next, we used Multi-Omics Factor Analysis (MOFA)³⁷ to perform unsupervised integration of
1083 all layers. We chose day 0, day 7 and day 35 as we had datasets for these time points
1084 across all layers for the highest ($N = 10$) and lowest ($N = 10$) responders. For transcriptome,
1085 the top highly variable genes were selected. For proteome and metabolome, we removed
1086 molecules that were significantly (nominal p-value < 0.05) associated with sex. Finally, we
1087 considered 1560 genes, 279 proteins and 158 metabolites across three timepoints for further
1088 analysis using MOFA. We applied MOFA standard practices and trained the model on a
1089 single group. The default data and training model options were used except for $scale_views$
1090 set to TRUE. Following model training, MOFA reported factor 1 correlated with technical
1091 variation and we thus did not consider this factor. The rest of the factors were evaluated for
1092 significance with either Responder Category, Age, Gender and Time by testing the factor
1093 values using a Wilcoxon ranked-sum test. For the factors that are shown, weights are scaled
1094 for each layer independently and used to identify the top predictors for proteome and
1095 metabolome. For network building, we performed GSEA using BTMs on the transcripts

1096 ranked by MOFA's scaled weights, and considered adjusted p-values < 0.05 significant. For
1097 proteome and metabolome, molecules with absolute scaled weights > 0.25 for factor 3 were
1098 considered and their associations done, similar to BTMs. Associations across layers of
1099 protein and metabolite molecules to different BTMs controlling for repeated measurements
1100 from the same donors were done and associations with adjusted p-values < 0.05 were
1101 selected. Across-layers associations were also calculated and significant associations were
1102 kept. Cytoscape⁸⁶ was used to build the multi-layer network with colour of the nodes
1103 representing factor 3 scaled weights for each protein or metabolite, or enrichment score for
1104 transcriptome BTMs.

1105

1106 *Partial least-squares regression*

1107 We employed partial least-squares regression (PLSR) to identify the pre-vaccination proteins
1108 and metabolites that are most consistently associated with the serological response against
1109 the three influenza strains. PLSR was performed using the *pls* library in R for proteome and
1110 metabolome separately using all 200 donors of the discovery cohort. The model was run for
1111 100 independent iterations with 10-fold cross-validations (e.g. 90% training, 10% testing)
1112 and we calculated the proportion of variation explained by each PLSR component. For the
1113 first 3 components we performed rank-product analysis over the 100 iterations to identify the
1114 top predictors. The top 30 ranked molecules (either proteins or metabolites) were then
1115 evaluated for their positive or negative association with antibody fold change.

1116

1117

1118

1119

1120

1121

1122

1123

1124 **SUPPLEMENTAL INFORMATION TITLES AND LEGEND**

1125

1126 **Supplementary Figure 1** *General demographic factors associated to the serological*
1127 *response to trivalent inactivated influenza vaccination. (A)* Correlation among
1128 hemagglutination (HAI) titers fold-change upon vaccination. In both seasons, HAI titers
1129 against each of the three strains are moderately positively correlated to each other. **(B)**
1130 Correlation between MN titers and HAI titers across two influenza seasons. Each dot is a
1131 sample, colours represent influenza strains. **(C)** Impact of sex on the serological response to
1132 TIV across two seasons. P-values were generated using the Wilcoxon ranked-sum test. **(D)**
1133 Influence of age on the HAI and microneutralization (MN) titers. Each dot is an individual,
1134 colours represent the different influenza strains.

1135

1136 **Supplementary Figure 2** *Differences in cellular populations between responders and non-*
1137 *responders. (A)* Deconvoluted cellular populations were estimated using CIBERSORT from
1138 bulk transcriptomics data (n=10 TR, n=10 NR) across five different timepoints. Each point
1139 indicates a sample (NR=blue, TR=red). The curve is a smooth fitted line with standard error
1140 of the estimation. **(B)** CBC at T1 (pre-vaccination) for Neutrophils, Leucocytes and
1141 Monocytes for 200 donors. Samples are stratified by their responder status: TR, Other or
1142 NR.

1143

1144 **Supplementary Figure 3** *Time dynamics and BTMs in TRs and NRs.* (A) Significant BTMs
1145 upregulated in TRs and NRs at pre-vaccination stage. (B) Genes enriched for inflammatory
1146 BTMs and their expression in TRs and NRs. Only CD83 and IL23A are significantly
1147 (adjusted p-value < 0.05) upregulated in TRs (C) Number of significantly differentially
1148 expressed genes in TRs and NRs, 3days, 7 days, 35 days and 70 days post vaccination (D)
1149 Top 20 significant BTMs upregulated and downregulated in TRs 3 days post vaccination. (E)
1150 BTMs significantly upregulated in TRs (left), NRs (right) 7 days post vaccination.

1151
1152 **Supplementary Figure 4** *NK cell flow cytometry results from the replication cohort.* Total NK
1153 cell proportions (top), CD56dim (middle) and CD56bright (bottom) flow cytometry results
1154 from NRs (n=2, except day 6/7 where n=1) and TRs (n=5).

1155
1156 **Supplementary Figure 5** *Proteomic and metabolomic response to TIV.* (A) CLECL7A
1157 proteome abundance in all TRs (red) and NRs (blue) over time in the Discovery cohort (top)
1158 and the Replication cohort (bottom). (B) Proteome differential abundance results in the
1159 replication cohort. (C) Volcano plots showing differential abundance results comparing Day
1160 35 vs Day 0 for TRs (left) and NRs (right) in discovery cohort. Red dots represent
1161 significantly different proteins at adjusted p-value < 0.05. (D) Annotation of the differentially
1162 abundant metabolites found in the replication cohort. Baseline represents the universe of all
1163 metabolites measured, whereas TR and NR show significantly differentially abundant
1164 metabolites (nominal p < 0.05) at T3 and T4, respectively. (E) Subclass annotation of
1165 upregulated organic acids (top) and lipids and lipid-like molecules (bottom). These
1166 metabolites were significantly differentially abundant (adjusted p < 0.05) in the discovery
1167 cohort. Pie charts indicate the distribution of significant metabolites within the fatty acids and
1168 conjugates classification. (F) Alluvial plot showing the differential expression results for TRs
1169 (left) and NRs (right) at the different timepoints compared to baseline in the discovery cohort
1170 (n=81). Significant metabolites shown (adjusted p-value < 0.05).

1171
1172 **Supplementary Figure 6** Proteins upregulated in NRs 7 days post vaccination and their
1173 correlation with transcriptome chronic inflammatory BTMs. Most proteins show a negative
1174 correlation with unadjusted p-value < 0.05.

1175
1176 **Supplementary Figure 7** *Multiomics integration capturing different dynamics in TRs and*
1177 *NRs.* (A) Factor 4 and Factor 6 showing time variation captured in TRs. Factor 4 is
1178 exclusively explained by transcriptome while factor 6 is explained by both transcriptome and
1179 proteome. (B) Abundance of top factor 3 proteins and metabolites in all 81 TRs and NRs. (C)
1180 Methionine positive correlation with cytokine production post influenza stimulation in 500FG
1181 cohort. (D) Distribution of scaled weights attributed to proteins, metabolites and enrichment
1182 score for transcripts. Molecules with scaled weights of absolute value > = 0.25 were
1183 considered for network generation in Figure 4E.

1184
1185 **Supplementary Figure 8** *Pre-vaccination correlates* (A) Plot of TNFSF13/APRIL against
1186 log2 antibody fold change of each strain in discovery (left) and replication cohort (right). (B)
1187 Plot of IL15 against antibody fold change of each strain in replication cohort. (C) Expression
1188 of IL-15 in human PBMCs using single-cell RNA sequencing data.

1189
1190 **Supplementary Figure 9** *IL15RA^{-/-} mice experiments* (A) Representative flow cytometry
1191 plots showing the frequency of B cells (CD19⁺) and T cells (CD3⁺) in the spleen of IL15RA^{-/-}

1192 mice (left plot), and the NK cell frequency (NK1.1+) among splenocytes from IL15RA^{+/+} and
1193 IL15RA^{-/-} mice (two plots on the right). **(B)** The dot plots represent the frequency of total B
1194 cells, GC B cells, total CD4+T cells, CD4+Foxp3- Tconv cells, CD4+Foxp3+ Treg cells, Tfh,
1195 and Tfr cells in inguinal lymph nodes from IL15RA^{+/+} and IL15RA^{-/-} mice. Pooled data from
1196 two independent experiments; n=8 to 10.

1197

1198 **Supplementary Figure 10** *Pre-vaccination metabolite correlates with antibody fold change.*

1199 **(A)** Plot of citric acid against antibody fold change for each strain. **(B)** Plot of citric acid
1200 abundance against cell proportions calculated from 300BCG cohort. **(C)** Plot of betaine(top)
1201 and cysteine(bottom) abundance against antibody fold change for each strain. **(D)** Additional
1202 unsaturated long chain fatty acids negatively correlated to IL15. **(E)** Estimate of protein (42)
1203 associations to all fatty acids for ~200 elderly donors (left) and to ~ 500 young donors (right).
1204 In the elderly, LCFA negatively correlated to most proteins while other fatty acids (FAs) show
1205 both positive and negative correlation while no such pattern observed in the younger cohort.
1206 Associations with p-value <0.05 plotted.

1207

1208 **Supplementary Figure 11** *Replicability of untargeted metabolomic profiles.* We manually

1209 correlated 19 primary amino acids that were confidently detected in both the untargeted and
1210 targeted metabolomics dataset. Each dot indicates a sample, coloured for time (10TRs,
1211 10NRs across three timepoints). We observe good replicability for the primary amino acids.

1212

1213

1214

1215

1216

1217

1218

1219

1220 REFERENCES

1221

1222 1. Iuliano, A.D., Roguski, K.M., Chang, H.H., Muscatello, D.J., Palekar, R., Tempia, S., Cohen, C., Gran, J.M., Schanzer, D.,
1223 Cowling, B.J., et al. (2018). Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.
1224 *The Lancet* 391, 1285–1300. 10.1016/S0140-6736(17)33293-2.

1225 2. Osterholm, M.T., Kelley, N.S., Sommer, A., and Belongia, E.A. (2012). Efficacy and effectiveness of influenza vaccines: a
1226 systematic review and meta-analysis. *The Lancet Infectious Diseases* 12, 36–44. 10.1016/S1473-3099(11)70295-X.

1227 3. Ferdinands, J.M., Thompson, M.G., Blanton, L., Spencer, S., Grant, L., and Fry, A.M. (2021). Does influenza vaccination
1228 attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. *Vaccine*
1229 39, 3678–3695. 10.1016/j.vaccine.2021.05.011.

1230 4. Lang, P.-O., Mendes, Socquet, Assir, Govind, and Aspinall (2012). Effectiveness of influenza vaccine in aging and older
1231 adults: comprehensive analysis of the evidence. *CIA*, 55. 10.2147/CIA.S25215.

1232 5. Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., and Demicheli, V. (2005). Efficacy and effectiveness of
1233 influenza vaccines in elderly people: a systematic review. *The Lancet* 366, 1165–1174. 10.1016/S0140-6736(05)67339-4.

1234 6. Goronzy, J.J., and Weyand, C.M. (2013). Understanding immunosenescence to improve responses to vaccines. *Nat*
1235 *Immunol* 14, 428–436. 10.1038/ni.2588.

1236 7. Riese, P., Trittel, S., Akmatov, M.K., May, M., Prokein, J., Illig, T., Schindler, C., Sawitzki, B., Elfaki, Y., Floess, S., et al.
1237 (2022). Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly.
1238 *Nat Commun* 13, 6894. 10.1038/s41467-022-34487-z.

- 1239 8. Nakaya, H.I., Hagan, T., Duraisingham, S.S., Lee, E.K., Kwissa, M., Roupael, N., Frasca, D., Gersten, M., Mehta, A.K.,
1240 Gaujoux, R., et al. (2015). Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse
1241 Populations Reveals Shared Molecular Signatures. *Immunity* 43, 1186–1198. 10.1016/j.immuni.2015.11.012.
- 1242 9. Nipper, A.J., Smithey, M.J., Shah, R.C., Canaday, D.H., and Landay, A.L. (2018). Diminished antibody response to
1243 influenza vaccination is characterized by expansion of an age-associated B-cell population with low PAX5. *Clinical*
1244 *Immunology* 193, 80–87. 10.1016/j.clim.2018.02.003.
- 1245 10. Frasca, D., Diaz, A., Romero, M., Garcia, D., and Blomberg, B.B. (2020). B Cell Immunosenescence. *Annu. Rev. Cell*
1246 *Dev. Biol.* 36, 551–574. 10.1146/annurev-cellbio-011620-034148.
- 1247 11. Wimmers, F., Donato, M., Kuo, A., Ashuach, T., Gupta, S., Li, C., Dvorak, M., Foecke, M.H., Chang, S.E., Hagan, T., et al.
1248 (2021). The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. *Cell* 184, 3915-
1249 3935.e21. 10.1016/j.cell.2021.05.039.
- 1250 12. Hagan, T., Cortese, M., Roupael, N., Boudreau, C., Linde, C., Maddur, M.S., Das, J., Wang, H., Guthmiller, J., Zheng,
1251 N.-Y., et al. (2019). Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. *Cell* 178,
1252 1313-1328.e13. 10.1016/j.cell.2019.08.010.
- 1253 13. Fourati, S., Tomalin, L.E., Mulè, M.P., Chawla, D.G., Gerritsen, B., Rychkov, D., Henrich, E., Miller, H.E.R., Hagan, T.,
1254 Diray-Arce, J., et al. (2022). Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to
1255 vaccination. *Nat Immunol* 23, 1777–1787. 10.1038/s41590-022-01329-5.
- 1256 14. Kelly, B., and Pearce, E.L. (2020). Amino Assets: How Amino Acids Support Immunity. *Cell Metabolism* 32, 154–175.
1257 10.1016/j.cmet.2020.06.010.
- 1258 15. Ganeshan, K., and Chawla, A. (2014). Metabolic Regulation of Immune Responses. *Annu. Rev. Immunol.* 32, 609–634.
1259 10.1146/annurev-immunol-032713-120236.
- 1260 16. Chou, C., Mohanty, S., Kang, H.A., Kong, L., Avila-Pacheco, J., Joshi, S.R., Ueda, I., Devine, L., Raddassi, K., Pierce, K.,
1261 et al. (2022). Metabolomic and transcriptomic signatures of influenza vaccine response in healthy young and older adults.
1262 *Aging Cell* 21. 10.1111/acer.13682.
- 1263 17. Akmatov, M.K., Riese, P., May, M., Jentsch, L., Ahmed, M.W., Werner, D., Rösel, A., Tyler, M., Pessler, K., Prokein, J., et
1264 al. (2017). Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly
1265 individuals recruited from the general population. *Human Vaccines & Immunotherapeutics* 13, 1630–1639.
1266 10.1080/21645515.2017.1299300.
- 1267 18. Akmatov, M.K., Jentsch, L., Riese, P., May, M., Ahmed, M.W., Werner, D., Rösel, A., Prokein, J., Bernemann, I., Klopp,
1268 N., et al. (2017). Motivations for (non)participation in population-based health studies among the elderly – comparison of
1269 participants and nonparticipants of a prospective study on influenza vaccination. *BMC Med Res Methodol* 17, 18.
1270 10.1186/s12874-017-0302-z.
- 1271 19. Akmatov, M.K., Riese, P., Trittel, S., May, M., Prokein, J., Illig, T., Schindler, C., Guzmán, C.A., and Pessler, F. (2019).
1272 Self-reported diabetes and herpes zoster are associated with a weak humoral response to the seasonal influenza A H1N1
1273 vaccine antigen among the elderly. *BMC Infect Dis* 19, 656. 10.1186/s12879-019-4214-x.
- 1274 20. Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means, A.R., Kasturi, S.P., Khan, N.,
1275 Li, G.-M., et al. (2011). Systems biology of vaccination for seasonal influenza in humans. *Nat Immunol* 12, 786–795.
1276 10.1038/ni.2067.
- 1277 21. Avey, S., Mohanty, S., Chawla, D.G., Meng, H., Bandaranayake, T., Ueda, I., Zapata, H.J., Park, K., Blevins, T.P., Tsang,
1278 S., et al. (2020). Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and
1279 Older Adults. *The Journal of Immunology* 204, 1661–1673. 10.4049/jimmunol.1900922.
- 1280 22. Olafsdottir, T.A., Alexandersson, K.F., Sveinbjornsson, G., Lapini, G., Palladino, L., Montomoli, E., Del Giudice, G.,
1281 Gudbjartsson, D.F., and Jonsdottir, I. (2018). Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect
1282 Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small Effects. *Front.*
1283 *Immunol.* 8, 1872. 10.3389/fimmu.2017.01872.
- 1284 23. Li, S., Roupael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton,
1285 A., Rajam, G., et al. (2014). Molecular signatures of antibody responses derived from a systems biology study of five
1286 human vaccines. *Nat Immunol* 15, 195–204. 10.1038/ni.2789.
- 1287 24. Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M., and Alizadeh, A.A.
1288 (2015). Robust enumeration of cell subsets from tissue expression profiles. *Nat Methods* 12, 453–457.
1289 10.1038/nmeth.3337.
- 1290 25. Wang, Y., Wang, X., Jia, X., Li, J., Fu, J., Huang, X., Cui, X., Wang, B., Luo, W., Lin, C., et al. (2023). Influenza
1291 vaccination features revealed by a single-cell transcriptome atlas. *Journal of Medical Virology* 95. 10.1002/jmv.28174.

- 1292 26. Koutsakos, M., Wheatley, A.K., Loh, L., Clemens, E.B., Sant, S., Nüssing, S., Fox, A., Chung, A.W., Laurie, K.L., Hurt,
1293 A.C., et al. (2018). Circulating T_{FH} cells, serological memory, and tissue compartmentalization shape human influenza-
1294 specific B cell immunity. *Sci. Transl. Med.* *10*, ean8405. [10.1126/scitranslmed.aan8405](https://doi.org/10.1126/scitranslmed.aan8405).
- 1295 27. Castigli, E., Wilson, S.A., Scott, S., Dedeoglu, F., Xu, S., Lam, K.-P., Bram, R.J., Jabara, H., and Geha, R.S. (2005). TAC1
1296 and BAFF-R mediate isotype switching in B cells. *Journal of Experimental Medicine* *201*, 35–39. [10.1084/jem.20032000](https://doi.org/10.1084/jem.20032000).
- 1297 28. Mantchev, G.T., Cortesão, C.S., Rebrovich, M., Cascalho, M., and Bram, R.J. (2007). TAC1 Is Required for Efficient
1298 Plasma Cell Differentiation in Response to T-Independent Type 2 Antigens. *The Journal of Immunology* *179*, 2282–2288.
1299 [10.4049/jimmunol.179.4.2282](https://doi.org/10.4049/jimmunol.179.4.2282).
- 1300 29. de Groen, R.A., Groothuisink, Z.M.A., Liu, B.-S., and Boonstra, A. (2015). IFN- λ is able to augment TLR-mediated
1301 activation and subsequent function of primary human B cells. *Journal of Leukocyte Biology* *98*, 623–630.
1302 [10.1189/jlb.3A0215-041RR](https://doi.org/10.1189/jlb.3A0215-041RR).
- 1303 30. Hemann, E.A., Green, R., Turnbull, J.B., Langlois, R.A., Savan, R., and Gale, M. (2019). Interferon- λ modulates dendritic
1304 cells to facilitate T cell immunity during infection with influenza A virus. *Nat Immunol* *20*, 1035–1045. [10.1038/s41590-019-0408-z](https://doi.org/10.1038/s41590-019-0408-z).
- 1306 31. Schaller, T.H., Batich, K.A., Suryadevara, C.M., Desai, R., and Sampson, J.H. (2017). Chemokines as adjuvants for
1307 immunotherapy: implications for immune activation with CCL3. *Expert Review of Clinical Immunology* *13*, 1049–1060.
1308 [10.1080/1744666X.2017.1384313](https://doi.org/10.1080/1744666X.2017.1384313).
- 1309 32. Pazzaglia, S., and Pioli, C. (2019). Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and
1310 Therapeutic Implications in Cancer and Non-Cancer Diseases. *Cells* *9*, 41. [10.3390/cells9010041](https://doi.org/10.3390/cells9010041).
- 1311 33. Shou, Q., Fu, H., Huang, X., and Yang, Y. (2019). PARP-1 controls NK cell recruitment to the site of viral infection. *JCI*
1312 *Insight* *4*, e121291. [10.1172/jci.insight.121291](https://doi.org/10.1172/jci.insight.121291).
- 1313 34. Wang, L., Niu, Z., Wang, X., Li, Z., Liu, Y., Luo, F., and Yan, X. (2020). PHD2 exerts anti-cancer and anti-inflammatory
1314 effects in colon cancer xenografts mice via attenuating NF- κ B activity. *Life Sciences* *242*, 117167.
1315 [10.1016/j.lfs.2019.117167](https://doi.org/10.1016/j.lfs.2019.117167).
- 1316 35. Bao, J., Pan, G., Poncz, M., Wei, J., Ran, M., and Zhou, Z. (2018). Serpin functions in host-pathogen interactions. *PeerJ*
1317 *6*, e4557. [10.7717/peerj.4557](https://doi.org/10.7717/peerj.4557).
- 1318 36. Battaglia, S., De Santis, S., Rutigliano, M., Sallustio, F., Picerno, A., Frassanito, M.A., Schaefer, I., Vacca, A., Moschetta,
1319 A., Seibel, P., et al. (2021). Uridine and pyruvate protect T cells' proliferative capacity from mitochondrial toxic antibiotics:
1320 a clinical pilot study. *Sci Rep* *11*, 12841. [10.1038/s41598-021-91559-8](https://doi.org/10.1038/s41598-021-91559-8).
- 1321 37. Argelaguet, R., Velten, B., Arnl, D., Dietrich, S., Zenz, T., Marioni, J.C., Buettner, F., Huber, W., and Stegle, O. (2018).
1322 Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets. *Mol Syst Biol* *14*.
1323 [10.15252/msb.20178124](https://doi.org/10.15252/msb.20178124).
- 1324 38. Bakker, O.B., Aguirre-Gamboa, R., Sanna, S., Oosting, M., Smeekens, S.P., Jaeger, M., Zorro, M., Vösa, U., Withoff, S.,
1325 Netea-Maier, R.T., et al. (2018). Integration of multi-omics data and deep phenotyping enables prediction of cytokine
1326 responses. *Nat Immunol* *19*, 776–786. [10.1038/s41590-018-0121-3](https://doi.org/10.1038/s41590-018-0121-3).
- 1327 39. Li, Y., Oosting, M., Smeekens, S.P., Jaeger, M., Aguirre-Gamboa, R., Le, K.T.T., Deelen, P., Ricaño-Ponce, I.,
1328 Schoffelen, T., Jansen, A.F.M., et al. (2016). A Functional Genomics Approach to Understand Variation in Cytokine
1329 Production in Humans. *Cell* *167*, 1099–1110.e14. [10.1016/j.cell.2016.10.017](https://doi.org/10.1016/j.cell.2016.10.017).
- 1330 40. Linden, J., Koch-Nolte, F., and Dahl, G. (2019). Purine Release, Metabolism, and Signaling in the Inflammatory
1331 Response. *Annu. Rev. Immunol.* *37*, 325–347. [10.1146/annurev-immunol-051116-052406](https://doi.org/10.1146/annurev-immunol-051116-052406).
- 1332 41. Idzko, M., Ferrari, D., and Eltzschig, H.K. (2014). Nucleotide signalling during inflammation. *Nature* *509*, 310–317.
1333 [10.1038/nature13085](https://doi.org/10.1038/nature13085).
- 1334 42. Nakamura, R., Maeda, N., Shibata, K., Yamada, H., Kase, T., and Yoshikai, Y. (2010). Interleukin-15 Is Critical in the
1335 Pathogenesis of Influenza A Virus-Induced Acute Lung Injury. *J Virol* *84*, 5574–5582. [10.1128/JVI.02030-09](https://doi.org/10.1128/JVI.02030-09).
- 1336 43. Verbist, K.C., Rose, D.L., Cole, C.J., Field, M.B., and Klonowski, K.D. (2012). IL-15 Participates in the Respiratory Innate
1337 Immune Response to Influenza Virus Infection. *PLoS ONE* *7*, e37539. [10.1371/journal.pone.0037539](https://doi.org/10.1371/journal.pone.0037539).
- 1338 44. Tran, A.T., Rahim, M.N., Ranadheera, C., Kroeker, A., Cortens, J.P., Opanubi, K.J., Wilkins, J.A., and Coombs, K.M.
1339 (2013). Knockdown of specific host factors protects against influenza virus-induced cell death. *Cell Death Dis* *4*, e769–
1340 e769. [10.1038/cddis.2013.296](https://doi.org/10.1038/cddis.2013.296).

- 1341 45. Debisarun, P.A., Gössling, K.L., Bulut, O., Kilic, G., Zoodsma, M., Liu, Z., Oldenburg, M., Rüchel, N., Zhang, B., Xu, C.-J.,
1342 et al. (2021). Induction of trained immunity by influenza vaccination - impact on COVID-19. *PLoS Pathog* *17*, e1009928.
1343 10.1371/journal.ppat.1009928.
- 1344 46. Carson, W.E., Giri, J.G., Lindemann, M.J., Linett, M.L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein,
1345 K., and Caligiuri, M.A. (1994). Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via
1346 components of the IL-2 receptor. *Journal of Experimental Medicine* *180*, 1395–1403. 10.1084/jem.180.4.1395.
- 1347 47. Ma, S., Caligiuri, M.A., and Yu, J. (2022). Harnessing IL-15 signaling to potentiate NK cell-mediated cancer
1348 immunotherapy. *Trends in Immunology* *43*, 833–847. 10.1016/j.it.2022.08.004.
- 1349 48. Huntington, N.D., Legrand, N., Alves, N.L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et
1350 al. (2009). IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. *Journal of*
1351 *Experimental Medicine* *206*, 25–34. 10.1084/jem.20082013.
- 1352 49. Rydyznski, C., Daniels, K.A., Karmele, E.P., Brooks, T.R., Mahl, S.E., Moran, M.T., Li, C., Sutiwisesak, R., Welsh, R.M.,
1353 and Waggoner, S.N. (2015). Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells.
1354 *Nat Commun* *6*, 6375. 10.1038/ncomms7375.
- 1355 50. Rydyznski, C.E., Cranert, S.A., Zhou, J.Q., Xu, H., Kleinstein, S.H., Singh, H., and Waggoner, S.N. (2018). Affinity
1356 Maturation Is Impaired by Natural Killer Cell Suppression of Germinal Centers. *Cell Reports* *24*, 3367-3373.e4.
1357 10.1016/j.celrep.2018.08.075.
- 1358 51. Wollenberg, I., Agua-Doce, A., Hernández, A., Almeida, C., Oliveira, V.G., Faro, J., and Graca, L. (2011). Regulation of
1359 the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells. *The Journal of Immunology* *187*, 4553–4560.
1360 10.4049/jimmunol.1101328.
- 1361 52. Stebegg, M., Kumar, S.D., Silva-Cayetano, A., Fonseca, V.R., Linterman, M.A., and Graca, L. (2018). Regulation of the
1362 Germinal Center Response. *Front. Immunol.* *9*, 2469. 10.3389/fimmu.2018.02469.
- 1363 53. Chu, X., Jaeger, M., Beumer, J., Bakker, O.B., Aguirre-Gamboa, R., Oosting, M., Smeekens, S.P., Moorlag, S., Mourits,
1364 V.P., Koeken, V.A.C.M., et al. (2021). Integration of metabolomics, genomics, and immune phenotypes reveals the causal
1365 roles of metabolites in disease. *Genome Biol* *22*, 198. 10.1186/s13059-021-02413-z.
- 1366 54. Aguirre-Gamboa, R., Joosten, I., Urbano, P.C.M., van der Molen, R.G., van Rijssen, E., van Cranenbroek, B., Oosting, M.,
1367 Smeekens, S., Jaeger, M., Zorro, M., et al. (2016). Differential Effects of Environmental and Genetic Factors on T and B
1368 Cell Immune Traits. *Cell Reports* *17*, 2474–2487. 10.1016/j.celrep.2016.10.053.
- 1369 55. Xia, Y., Chen, S., Zhu, G., Huang, R., Yin, Y., and Ren, W. (2018). Betaine Inhibits Interleukin-1 β Production and
1370 Release: Potential Mechanisms. *Front. Immunol.* *9*, 2670. 10.3389/fimmu.2018.02670.
- 1371 56. Zhao, G., He, F., Wu, C., Li, P., Li, N., Deng, J., Zhu, G., Ren, W., and Peng, Y. (2018). Betaine in Inflammation:
1372 Mechanistic Aspects and Applications. *Front. Immunol.* *9*, 1070. 10.3389/fimmu.2018.01070.
- 1373 57. Go, E.K., Jung, K.J., Kim, J.Y., Yu, B.P., and Chung, H.Y. (2005). Betaine Suppresses Proinflammatory Signaling During
1374 Aging: The Involvement of Nuclear Factor- κ B via Nuclear Factor-Inducing Kinase/ I κ B Kinase and Mitogen-Activated
1375 Protein Kinases. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences* *60*, 1252–1264.
1376 10.1093/gerona/60.10.1252.
- 1377 58. Eggersdorfer, M., Berger, M.M., Calder, P.C., Gombart, A.F., Ho, E., Laviano, A., and Meydani, S.N. (2022). Perspective:
1378 Role of Micronutrients and Omega-3 Long-Chain Polyunsaturated Fatty Acids for Immune Outcomes of Relevance to
1379 Infections in Older Adults—A Narrative Review and Call for Action. *Advances in Nutrition* *13*, 1415–1430.
1380 10.1093/advances/nmac058.
- 1381 59. Venn-Watson, S.K., and Butterworth, C.N. (2022). Broader and safer clinically-relevant activities of pentadecanoic acid
1382 compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease
1383 systems. *PLoS ONE* *17*, e0268778. 10.1371/journal.pone.0268778.
- 1384 60. Venn-Watson, S., Lumpkin, R., and Dennis, E.A. (2020). Efficacy of dietary odd-chain saturated fatty acid pentadecanoic
1385 acid parallels broad associated health benefits in humans: could it be essential? *Sci Rep* *10*, 8161. 10.1038/s41598-020-
1386 64960-y.
- 1387 61. Riese, P., Trittel, S., Pathirana, R.D., Klawonn, F., Cox, R.J., and Guzmán, C.A. (2020). Responsiveness to Influenza
1388 Vaccination Correlates with NKG2C-Expression on NK Cells. *Vaccines* *8*, 281. 10.3390/vaccines8020281.
- 1389 62. Pereira, B., Xu, X.-N., and Akbar, A.N. (2020). Targeting Inflammation and Immunosenescence to Improve Vaccine
1390 Responses in the Elderly. *Front. Immunol.* *11*, 583019. 10.3389/fimmu.2020.583019.

- 1391 63. Kathuria, N., Kraynyak, K.A., Carnathan, D., Betts, M., Weiner, D.B., and Kutzler, M.A. (2012). Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant. *Human Vaccines & Immunotherapeutics* 8, 1607–1619. 10.4161/hv.22574.
1392
1393
- 1394 64. Barbul, A., Sisto, D., Wasserkrug, L., and Efron, G. (1981). Arginine stimulates lymphocyte immune response in healthy human beings. *Surgery* 90, 244–251.
1395
- 1396 65. Moriguti, J.C., Ferrioli, E., Donadi, E.A., and Marchini, J.S. (2005). Effects of arginine supplementation on the humoral and innate immune response of older people. *Eur J Clin Nutr* 59, 1362–1366. 10.1038/sj.ejcn.1602247.
1397
- 1398 66. Wu, X., Sun, M., Yang, Z., Lu, C., Wang, Q., Wang, H., Deng, C., Liu, Y., and Yang, Y. (2021). The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. *Front. Cell Dev. Biol.* 9, 686548.
1399 10.3389/fcell.2021.686548.
1400
- 1401 67. Ferrero, M.R., Tavares, L.P., and Garcia, C.C. (2022). The Dual Role of CCR5 in the Course of Influenza Infection: Exploring Treatment Opportunities. *Front. Immunol.* 12, 826621. 10.3389/fimmu.2021.826621.
1402
- 1403 68. Cox, A., Cevik, H., Feldman, H.A., Canaday, L.M., Lakes, N., and Waggoner, S.N. (2021). Targeting natural killer cells to enhance vaccine responses. *Trends in Pharmacological Sciences* 42, 789–801. 10.1016/j.tips.2021.06.004.
1404
- 1405 69. Frank, K., and Paust, S. (2020). Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection. *Front. Cell. Infect. Microbiol.* 10, 425. 10.3389/fcimb.2020.00425.
1406
- 1407 70. Mooney, J.P., Qendro, T., Keith, M., Philbey, A.W., Groves, H.T., Tregoning, J.S., Goodier, M.R., and Riley, E.M. (2020). Natural Killer Cells Dampen the Pathogenic Features of Recall Responses to Influenza Infection. *Front. Immunol.* 11, 135. 10.3389/fimmu.2020.00135.
1408
1409
- 1410 71. Lee, N., Shin, M.S., Kang, K.S., Yoo, S.-A., Mohanty, S., Montgomery, R.R., Shaw, A.C., and Kang, I. (2014). Human monocytes have increased IFN- γ -mediated IL-15 production with age alongside altered IFN- γ receptor signaling. *Clinical Immunology* 152, 101–110. 10.1016/j.clim.2014.03.003.
1411
1412
- 1413 72. Bouchard, A., Rattthé, C., and Girard, D. (2004). Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. *Journal of Leukocyte Biology* 75, 893–900. 10.1189/jlb.1103585.
1414
1415
- 1416 73. Moretta, A. (2002). Natural killer cells and dendritic cells: rendezvous in abused tissues. *Nat Rev Immunol* 2, 957–965. 10.1038/nri956.
1417
- 1418 74. Graca, L., Faria, A.C., and Ribeiro, R.M. (2023). Illuminating a blind spot in SARS-CoV-2 immunity. *Nat Immunol* 24, 889–890. 10.1038/s41590-023-01518-w.
1419
- 1420 75. Zhang, W., Kedzierski, L., Chua, B.Y., Mayo, M., Lonzi, C., Rigas, V., Middleton, B.F., McQuilten, H.A., Rowntree, L.C., Allen, L.F., et al. (2023). Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. *Nat Immunol* 24, 966–978. 10.1038/s41590-023-01508-y.
1421
1422
- 1423 76. Fuhrer, T., Heer, D., Begemann, B., and Zamboni, N. (2011). High-Throughput, Accurate Mass Metabolome Profiling of Cellular Extracts by Flow Injection–Time-of-Flight Mass Spectrometry. *Anal. Chem.* 83, 7074–7080. 10.1021/ac201267k.
1424
- 1425 77. Arshad, H., Siokis, A., Franke, R., Habib, A., Alfonso, J.C.L., Poliakov, Y., Lücke, E., Michaelis, K., Brönstrup, M., Meyer-Hermann, M., et al. (2022). Reprogramming of Amino Acid Metabolism Differs between Community-Acquired Pneumonia and Infection-Associated Exacerbation of Chronic Obstructive Pulmonary Disease. *Cells* 11, 2283. 10.3390/cells11152283.
1426
1427
1428
- 1429 78. Assarsson, E., Lundberg, M., Holmquist, G., Björkstén, J., Bucht Thorsen, S., Ekman, D., Eriksson, A., Rennel Dickens, E., Ohlsson, S., Edfeldt, G., et al. (2014). Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability. *PLoS ONE* 9, e95192. 10.1371/journal.pone.0095192.
1430
1431
- 1432 79. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* 14, 417–419. 10.1038/nmeth.4197.
1433
- 1434 80. Sonesson, C., Love, M.I., and Robinson, M.D. (2016). Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* 4, 1521. 10.12688/f1000research.7563.2.
1435
- 1436 81. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research* 43, e47–e47. 10.1093/nar/gkv007.
1437
1438
- 1439 82. Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014). voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* 15, R29. 10.1186/gb-2014-15-2-r29.
1440

- 1441
1442
1443
83. Wishart, D.S., Feunang, Y.D., Marcu, A., Guo, A.C., Liang, K., Vázquez-Fresno, R., Sajed, T., Johnson, D., Li, C., Karu, N., et al. (2018). HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Research* *46*, D608–D617. 10.1093/nar/gkx1089.
- 1444
1445
1446
84. Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018). DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Research* *46*, D1074–D1082. 10.1093/nar/gkx1037.
- 1447
1448
85. Kamburov, A., Cavill, R., Ebbels, T.M.D., Herwig, R., and Keun, H.C. (2011). Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. *Bioinformatics* *27*, 2917–2918. 10.1093/bioinformatics/btr499.
- 1449
1450
86. Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.-L., and Ideker, T. (2011). Cytoscape 2.8: new features for data integration and network visualization. *Bioinformatics* *27*, 431–432. 10.1093/bioinformatics/btq675.
- 1451
- 1452
- 1453






Figure 1


A




B




E



C All transcription upregulated in TR vs NR genes consistently up NRs: 674 genes



D



Scaled BTM expression



NR_day0 NR_day3 NR_day7 NR_day35 NR_day70 TR_day0 TR_day3 TR_day7 TR_day35 TR_day70





Figure 2




Figure 3






Figure 4


A




B




C




D




E




F




G



H



I



Evidence

Proteome

Transcriptome

Experiments

Figure 5

